<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">30183728</article-id><article-id pub-id-type="pmc">6124765</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0203030</article-id><article-id pub-id-type="publisher-id">PONE-D-18-21369</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancer Treatment</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Carcinogenesis</subject><subj-group><subject>Cancer Stem Cells</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Cellular Types</subject><subj-group><subject>Animal Cells</subject><subj-group><subject>Stem Cells</subject><subj-group><subject>Cancer Stem Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Cellular Types</subject><subj-group><subject>Animal Cells</subject><subj-group><subject>Stem Cells</subject><subj-group><subject>Tumor Stem Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Cellular Types</subject><subj-group><subject>Animal Cells</subject><subj-group><subject>Stem Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Immune Physiology</subject><subj-group><subject>Cytokines</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Immune Physiology</subject><subj-group><subject>Cytokines</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune System</subject><subj-group><subject>Innate Immune System</subject><subj-group><subject>Cytokines</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune System</subject><subj-group><subject>Innate Immune System</subject><subj-group><subject>Cytokines</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Developmental Biology</subject><subj-group><subject>Molecular Development</subject><subj-group><subject>Cytokines</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancers and Neoplasms</subject><subj-group><subject>Differentiated Tumors</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Cellular Types</subject><subj-group><subject>Animal Cells</subject><subj-group><subject>Blood Cells</subject><subj-group><subject>White Blood Cells</subject><subj-group><subject>T Helper Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Cellular Types</subject><subj-group><subject>Animal Cells</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>White Blood Cells</subject><subj-group><subject>T Helper Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>White Blood Cells</subject><subj-group><subject>T Helper Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>White Blood Cells</subject><subj-group><subject>T Helper Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancer Treatment</subject><subj-group><subject>Cancer Immunotherapy</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Clinical Medicine</subject><subj-group><subject>Clinical Immunology</subject><subj-group><subject>Immunotherapy</subject><subj-group><subject>Cancer Immunotherapy</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Clinical Immunology</subject><subj-group><subject>Immunotherapy</subject><subj-group><subject>Cancer Immunotherapy</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Clinical Immunology</subject><subj-group><subject>Immunotherapy</subject><subj-group><subject>Cancer Immunotherapy</subject></subj-group></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Exploring immuno-regulatory mechanisms in the tumor microenvironment: Model and design of protocols for cancer remission</article-title><alt-title alt-title-type="running-head">Immune-regulation in tumor microenvironment</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ganguli</surname><given-names>Piyali</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-7115-163X</contrib-id><name><surname>Sarkar</surname><given-names>Ram Rup</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>Chemical Engineering and Process Development Division, CSIR-National Chemical Laboratory, Pune, Maharashtra, India</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Academy of Scientific &#x00026; Innovative Research (AcSIR), CSIR-NCL Campus, Pune, India</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Papaccio</surname><given-names>Gianpaolo</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>Universit&#x000e0; degli Studi della Campania, ITALY</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><corresp id="cor001">* E-mail: <email>rr.sarkar@ncl.res.in</email></corresp></author-notes><pub-date pub-type="epub"><day>5</day><month>9</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>13</volume><issue>9</issue><elocation-id>e0203030</elocation-id><history><date date-type="received"><day>19</day><month>7</month><year>2018</year></date><date date-type="accepted"><day>14</day><month>8</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; 2018 Ganguli, Sarkar</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>Ganguli, Sarkar</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0203030.pdf"/><abstract><p>The tumor microenvironment comprising of the immune cells and cytokines acts as the &#x02018;soil&#x02019; that nourishes a developing tumor. Lack of a comprehensive study of the interactions of this tumor microenvironment with the heterogeneous sub-population of tumor cells that arise from the differentiation of Cancer Stem Cells (CSC), i.e. the &#x02018;seed&#x02019;, has limited our understanding of the development of drug resistance and treatment failures in Cancer. Based on this seed and soil hypothesis, for the very first time, we have captured the concept of CSC differentiation and tumor-immune interaction into a generic model that has been validated with known experimental data. Using this model we report that as the CSC differentiation shifts from symmetric to asymmetric pattern, resistant cancer cells start accumulating in the tumor that makes it refractory to therapeutic interventions. Model analyses unveiled the presence of feedback loops that establish the dual role of M2 macrophages in regulating tumor proliferation. The study further revealed oscillations in the tumor sub-populations in the presence of T<sub>H1</sub> derived IFN-&#x003b3; that eliminates CSC; and the role of IL10 feedback in the regulation of T<sub>H1</sub>/T<sub>H2</sub> ratio. These analyses expose important observations that are indicative of Cancer prognosis. Further, the model has been used for testing known treatment protocols to explore the reasons of failure of conventional treatment strategies and propose an improvised protocol that shows promising results in suppressing the proliferation of all the cellular sub-populations of the tumor and restoring a healthy T<sub>H1</sub>/T<sub>H2</sub> ratio that assures better Cancer remission.</p></abstract><funding-group><award-group id="award001"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100001843</institution-id><institution>Science and Engineering Research Board</institution></institution-wrap></funding-source><award-id>EMR/2016/000516</award-id><principal-award-recipient><name><surname>Sarkar</surname><given-names>Ram Rup</given-names></name></principal-award-recipient></award-group><award-group id="award002"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100001412</institution-id><institution>Council of Scientific and Industrial Research</institution></institution-wrap></funding-source><award-id>Junior Research Fellowship</award-id><principal-award-recipient><name><surname>Ganguli</surname><given-names>Piyali</given-names></name></principal-award-recipient></award-group><funding-statement>We thank SERB, Department of Science and technology, Govt. of India (file no. EMR/2016/000516), for providing financial support to Ram Rup Sarkar. Piyali Ganguli acknowledges Council of Scientific &#x00026; Industrial Research (CSIR) for the Junior Research Fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="6"/><table-count count="0"/><page-count count="25"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the manuscript and its Supporting Information files.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the manuscript and its Supporting Information files.</p></notes></front><body><sec id="sec001"><title>1. Introduction</title><p>A malignant tumor is formed of heterogeneous population of cells. According to Cancer Stem Cell (CSC) Hypothesis, this tumor of heterogeneous cells is formed from a distinct group of cells having stem-like properties that are able to differentiate and renew for an indefinite period of time [<xref rid="pone.0203030.ref001" ref-type="bibr">1</xref>]. Popularly referred to as the Seed and Soil hypothesis, researchers believe that the CSCs acts like &#x02018;seed&#x02019; and form the tumor initiating population of cells, that is responsible for the growth, sustenance, metastasis and relapse of Cancer [<xref rid="pone.0203030.ref002" ref-type="bibr">2</xref>]. These CSCs have the ability to differentiate both symmetrically and asymmetrically to form the terminally differentiated cancer cells as well as renew the pool of CSCs [<xref rid="pone.0203030.ref003" ref-type="bibr">3</xref>]. However, during proliferation, various extrinsic and intrinsic environmental factors give rise to random mutational events, such as, chromosomal breakage, translocation, aberrant signalling events and drug efflux, which are responsible for transformation and adaptation of the cell to resist the effect of drug and conventional therapeutic strategies [<xref rid="pone.0203030.ref004" ref-type="bibr">4</xref>]. This results in the formation of distinct cellular sub-populations that are drug resistant and impair the treatment of cancer.</p><p>On the other hand, the tumor microenvironment, composed mainly of the immune cells and the cytokines, plays a crucial role in determining cancer prognosis [<xref rid="pone.0203030.ref005" ref-type="bibr">5</xref>]. As the tumor develops, each of the tumor cell sub-populations starts manipulating the microenvironment and induces the production of pro-tumorigenic molecules. The CSCs and the Cancer cells induce the production of immune-modulatory molecules such as IL-10, IL-13 and TGF-&#x003b2; that are conducive to the proliferation of the M2-Tumor Associated Macrophages (M2-TAM), the Type II T-helper (T<sub>H2</sub>) cells and the T-regulatory (Treg) cells [<xref rid="pone.0203030.ref006" ref-type="bibr">6</xref>, <xref rid="pone.0203030.ref007" ref-type="bibr">7</xref>]. The IL-10 mediated positive feedback loop between the tumor and the M2-TAMs helps in the rapid proliferation of the tumor sub-populations and the progression of the disease [<xref rid="pone.0203030.ref008" ref-type="bibr">8</xref>]. The CSCs also expresses high levels of co-inhibitory molecule PD-L1 that inhibit the activation of Cytotoxic T (Tc) cells [<xref rid="pone.0203030.ref009" ref-type="bibr">9</xref>]. Additionally, the CSC also tries to evade recognition by the immune cell by suppressing the expression of Major Histocompatibility Complex (MHC) by the macrophage cells in the tumor microenvironment. This is achieved by the release of exosomal miRNAs, such as miR-9 and miR-21, into the microenvironment by the tumor that are taken up by the immune cells, mediating changes in the cytokine expression pattern, antigen-recognition and immune responses [<xref rid="pone.0203030.ref010" ref-type="bibr">10</xref>, <xref rid="pone.0203030.ref011" ref-type="bibr">11</xref>]. Along with these strategies of immune evasion, CSC also secretes VEGF, a growth factor that promotes angiogenesis during tumor progression and plays a pivotal role in suppressing the maturation of the T cells [<xref rid="pone.0203030.ref012" ref-type="bibr">12</xref>, <xref rid="pone.0203030.ref013" ref-type="bibr">13</xref>]. These chemokines, cytokines and growth factors secreted by the stem cells lead the system to an inflammatory state. This also mediates a crosstalk between different groups of cells in the tumor microenvironment that are crucial for cancer initiation, progression and metastases formation [<xref rid="pone.0203030.ref014" ref-type="bibr">14</xref>, <xref rid="pone.0203030.ref015" ref-type="bibr">15</xref>]. These regulatory mechanisms that operate in the tumor microenvironment serve to suppress the anti-tumorigenic effect of the Cytotoxic T (Tc) cells and the Type I T-helper (T<sub>H1</sub>) cells. This immune-suppressed tumor microenvironment acts as the &#x02018;soil&#x02019; that nourishes and augments the growth of both the drug-sensitive as well as the drug-resistant sub-populations of the tumor, thereby posing a further challenge to the therapeutic strategies adopted to control cancer [<xref rid="pone.0203030.ref016" ref-type="bibr">16</xref>]. However, literature evidences showing the presence of a few tumor associated antigens (TAA) that helps in the recognition of these tumor cell sub-populations by the infiltrated T cells and the generation of effective immune responses upon Dendritic Cell (DC) vaccination throws light on the possibility of control of the disease using immunotherapy [<xref rid="pone.0203030.ref017" ref-type="bibr">17</xref>]. Hence a thorough understanding of the tumor-immune interaction, considering tumor sub-populations, is crucial to overcome the immune-suppression induced by the tumor.</p><p>In order to gain insight into the regulatory mechanisms governing these tumor-immune interactions, several studies have been performed using both theoretical as well as experimental techniques. Such studies have clearly indicated the role of Tc cells and IFN-&#x003b3; in controlling Cancer progression [<xref rid="pone.0203030.ref018" ref-type="bibr">18</xref>]. Recent findings have suggested that synergistic activation of Tc cells and &#x003b3;&#x003b4;-T cells are efficacious against HMLER-derived Breast Cancer stem-like cells, where &#x003b3;&#x003b4;-T cells act as an early source of IFN-&#x003b3; in tumor immunity, under special <italic>in vitr</italic>o conditions [<xref rid="pone.0203030.ref019" ref-type="bibr">19</xref>]. The development of Chimeric Antigen Receptor (CAR) T-cell has opened up new avenues for research in tumor immunity [<xref rid="pone.0203030.ref020" ref-type="bibr">20</xref>]. However, lack of truly CSC specific markers leads to on-target/off-tumor toxicity, where the CAR-T cells or any other CSC-targeted therapy kills the normal cells as well that display the same markers as that of CSCs [<xref rid="pone.0203030.ref020" ref-type="bibr">20</xref>, <xref rid="pone.0203030.ref021" ref-type="bibr">21</xref>].</p><p>Mathematical models have been useful in delineating the multiplicity of the complex interactions governing the dynamics of the tumor-immune interaction that remains elusive through <italic>in-vitro</italic> experiments. In this context, <italic>in-silico</italic> studies have shown light on the CSC differentiation pattern and its effect on the tumor growth dynamics [<xref rid="pone.0203030.ref003" ref-type="bibr">3</xref>]. Here it has been observed that symmetric stem cell division shows a correlation with cancer progression [<xref rid="pone.0203030.ref003" ref-type="bibr">3</xref>]. This is in contrast to another report that mentions symmetric stem cell division lowers cancer risk as it reduces the accumulation of cellular damage [<xref rid="pone.0203030.ref022" ref-type="bibr">22</xref>]. However, the effect of CSC differentiation on drug-resistivity and the outcome of the interaction of these differentiated cells with the tumor microenvironment have not been explored sufficiently. On the other hand, models on tumor-immune interaction considering the involvement of tumor, immune effector cell and IL2 have enhanced our understanding about oscillations in tumor sizes, long-term tumor relapse and the conditions under which tumor elimination may be achieved using Adoptive Cellular Immunotherapy [<xref rid="pone.0203030.ref023" ref-type="bibr">23</xref>]. Mathematical models are now being exploited for the study of the efficacy of adaptive immunity for the elimination of aggressive tumors [<xref rid="pone.0203030.ref024" ref-type="bibr">24</xref>, <xref rid="pone.0203030.ref025" ref-type="bibr">25</xref>], the existence of an angiogenic switch that regulates Cancer progression [<xref rid="pone.0203030.ref026" ref-type="bibr">26</xref>] and as a powerful tool in the design of optimal control strategies for Cancer [<xref rid="pone.0203030.ref027" ref-type="bibr">27</xref>, <xref rid="pone.0203030.ref028" ref-type="bibr">28</xref>].</p><p>However, the study of the CSC differentiation pattern and the outcome of the interaction of these heterogeneous tumor cell sub-populations with the immune cells and cytokines present in the microenvironment is a challenge yet to be achieved in both experiments as well as modelling studies. With the aim to gain a clearer and unambiguous picture of the regulatory mechanisms involved in the immune-escape mechanism of the tumor cells, we propose an ODE-based mathematical model of the tumor-immune interaction that captures the development of a malignant tumor from the &#x02018;seed&#x02019;, the CSCs, and its interaction with the &#x02018;soil&#x02019;, the tumor microenvironment. In this model, we consider the three different modes of CSC differentiation, as well as the effect of random mutations and ask the question, how the stem cell differentiation patterns regulate the different cellular sub-populations in the tumor and how it affects the development of drug resistance? Using this model we have tried to address the unresolved question of the correlation of M2 macrophages with more resistant tumors by exploring the regulatory feedback loops that govern the dynamics of the tumor-sub-population and the roles of the cytokine feedbacks in shaping the tumor microenvironment. Prior to these studies, the model has been calibrated and the unknown parameters of the model have been estimated by fitting the initial growth kinetics of the model with data obtained from Gastric Cancer cell line using the MCMC-DRAM algorithm [<xref rid="pone.0203030.ref029" ref-type="bibr">29</xref>]. Moreover, the steady state behaviors of all the model variables have been quantifiably validated with previously reported experimental data obtained from cytometric and protein expression studies from both <italic>in-vitro</italic> studies as well as data obtained from different Cancer patients to establish the generic behavior of our model and ensure its acceptability in the design of treatment strategies.</p><p>In order to design treatment protocols for triggering the Cancer remission, we have introduced radio and chemotherapeutic strategies and observed the fold changes in the tumor mass in the presence and in the absence of resistant cells, where we demonstrate the failure of the conventional treatment strategies for curing Cancer. Thereafter, we have ventured the use of immunotherapy that has also been a popular choice for the elimination of the CSCs that are resistant to chemo and radio-therapeutic interventions [<xref rid="pone.0203030.ref017" ref-type="bibr">17</xref>, <xref rid="pone.0203030.ref030" ref-type="bibr">30</xref>]. Hence, using the leads from our model analysis, we have attempted to propose combinatorial treatment strategies and design protocols that help in better suppression of the tumor, even in the presence of resistant cells. However, it may be mentioned here that a vital assumption in our model is that the drug-sensitive and drug-resistant population of tumor cells elicits similar immune responses. The resistant population of cells represents a fraction of the tumor cells that are unresponsive to the conventional treatment strategies. Thus, the difference in their behavior arises when the treatment/control is applied. Our novel modeling approach and strategy for the design of treatment protocol throws light on the ways to optimize drug schedules, dosage and treatment cycles required for the elimination of the tumor cells. This model may be used as a potential tool for the prediction of Cancer prognosis and calculation of fold changes in the tumor sub-populations in response to a new treatment regimen.</p></sec><sec id="sec002"><title>2. Model</title><p>The tumor-immune interaction model, depicted in <xref ref-type="fig" rid="pone.0203030.g001">Fig 1A</xref>, can be perceived as three regulatory modules &#x02013; (i) the core tumor along with the tumor infiltrated Tc cells (red box), (ii) the immune-stimulators consisting of M1 cells, T<sub>H1</sub> cells, IL2 and IFN-&#x003b3; cytokines (green box) and (c) the immune-suppressors consisting of M2 cells, T<sub>H2</sub> cell, Treg cells and IL10 cytokines (orange box). The interactions between these components of the model are based on known experimental evidences and immunological relevance. A detailed description of the model along with the mathematical assumptions, based on the biological phenomenon, used in its mathematical formulation has been described in the <italic>Methods</italic> section.</p><fig id="pone.0203030.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0203030.g001</object-id><label>Fig 1</label><caption><title>Diagrammatic representation of the tumor-immune interaction model.</title><p>(a) Cellular interaction network representing the key players of the tumor microenvironment, viz. Cancer Stem Cells (S), Cancer cells (C), their drug resistant counterparts (S<sub>R</sub> and C<sub>R</sub>), M1-TAM, M2-TAM, T<sub>H1</sub>, T<sub>H2</sub>, Tc, Treg immune cells, and cytokines IL10, IFN-&#x003b3; and IL-2; The tumor microenvironment has been grouped into three parts, <italic>viz</italic>.- core tumor and infiltrated Tc cells (red box), the immune-stimulators (green box) and the immune-suppressors (orange box); the Black arrows represent Activation, while the Red arrow represent Inhibition; (b) Stem cell differentiation pattern.</p></caption><graphic xlink:href="pone.0203030.g001"/></fig><p>Based on these biological relevances and mathematical assumptions, the tumor-immune interaction network has been modelled using 13 Ordinary Differential Equations (Eqs <xref ref-type="disp-formula" rid="pone.0203030.e005">1</xref>&#x02013;<xref ref-type="disp-formula" rid="pone.0203030.e017">13</xref>) and 71 parameters (as enlisted in the <italic>Methods</italic> section). The state variables and parameters used in the formulation of the model have been listed in the <xref ref-type="supplementary-material" rid="pone.0203030.s001">S1 Text</xref>. The initial values of the model variables have been listed in the <xref ref-type="supplementary-material" rid="pone.0203030.s001">S1 Text</xref>. Here the initial value of the stem cell S<sub>0</sub> = 1, while S<sub>R</sub>, C, C<sub>R</sub> have been initialized as zero such that all the tumor sub-populations develop from the symmetric and asymmetric differentiation of a single stem cell that ensures the conservation of the stem cell hypothesis.</p></sec><sec id="sec003"><title>3. Therapeutic intervention</title><p>The protocols are designed using various combinations of <italic>Radiotherapy</italic>, <italic>Chemotherapy</italic> and <italic>Immunotherapy</italic>. The dosage, time duration and number of cycles for each therapy are varied to determine the optimal combination that gives us maximum fold changes in the tumor reduction as well as enhance the T<sub>H1</sub>/T<sub>H2</sub> ratio to ensure better treatment efficacy. Two treatment protocols have been tested in our model. Protocol 1 is an adaptation from a previously reported protocol involving Chemotherapy and Radiotherapy, while Protocol 2 is novel combinatorial protocol proposed where we have introduced Immunotherapy by triggering the immune cells of our model (detailed discussion in the <italic>Methods</italic> section).</p></sec><sec id="sec004"><title>4. Results</title><sec id="sec005"><title>4.1. Model validation with experimental data</title><sec id="sec006"><title>4.1.1. Tumor growth (without therapy)</title><p>The growth kinetics of the tumor is estimated by four variables of our model, S, S<sub>R</sub>, C and C<sub>R</sub>, signifying the four sub-populations of cells that are found in the tumor. In order to validate the growth kinetics of these tumor cell sub-populations of our model, we have used data from different experimental and theoretical studies of tumor growth estimation. The early temporal growth kinetics of the Stem (S) and Resistant Stem cells (S<sub>R</sub>) were validated over a period of 5 days, with the reports of Tomasetti and Levy [<xref rid="pone.0203030.ref003" ref-type="bibr">3</xref>], by choosing the parameter values &#x003b3;<sub>S</sub> = 2 day<sup>-1</sup> and &#x003b4;<sub>S</sub> = 0.2 day<sup>-1</sup> (<xref ref-type="fig" rid="pone.0203030.g002">Fig 2A</xref>). Here, it was observed that the Stem cells (S) start proliferating exponentially during this initial growth phase of tumor formation. During this time frame, the stem cells also start acquiring mutations and start producing the Resistant Stem Cells (S<sub>R</sub>) that gradually starts proliferating slowly and is maintained in very low numbers inside the tumor [<xref rid="pone.0203030.ref003" ref-type="bibr">3</xref>]. It is to be noted that for all our subsequent simulations we have used &#x003b3;<sub>S</sub> = 0.15 day<sup>-1</sup> and &#x003b4;<sub>S</sub> = 2 x10<sup>-7</sup>day<sup>-1</sup>, as reported in the <xref ref-type="supplementary-material" rid="pone.0203030.s001">S1 Text</xref>.</p><fig id="pone.0203030.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0203030.g002</object-id><label>Fig 2</label><caption><p><bold>Model validation with experimental data:</bold> (a) Stem and Stem resistant cell proliferation at &#x003b3;<sub>S</sub> = 2 day<sup>-1</sup> and &#x003b4;<sub>S</sub> = 0.2 day<sup>-1</sup>; (b) Proliferation of the Cancer Resistant cells as observed in experiments along with the observations from our simulation; figure depicts growth kinetics of the Breast cancer cell line MCF-7/TAX-resistant to Paclitaxel, Hepatocellular Carcinoma cell line SK-Hep1/CDDP3-resistant to Cisplatin, and Colon Cancer cell lines SW-620-L-OHP and LoVo-L-OHP-resistant to Oxaliplatin; (c) Temporal cellular behavior of the components of the model during tumor formation; (d) Temporal cytokine expression pattern during tumor formation; (e) Immune Cell Ratio at steady state- experiment versus simulation results (f) Immune cell ratio in the disease free condition versus cancer scenario. Note: CD4 = T<sub>H1</sub> + T<sub>H2</sub>; CD8 = Tc.</p></caption><graphic xlink:href="pone.0203030.g002"/></fig><p>Temporal behaviors of the Cancer (C) and Resistant Cancer (C<sub>R</sub>) sub-populations have been simulated to validate our model with experimental data (<xref ref-type="fig" rid="pone.0203030.g002">Fig 2B</xref>; See <xref ref-type="sec" rid="sec018">Methods</xref>
<italic>Section 7</italic>.<italic>7</italic>). <xref ref-type="fig" rid="pone.0203030.g002">Fig 2B</xref> depicts the temporal growth kinetics of the Breast cancer cell line MCF-7/TAX-resistant to Paclitaxel [<xref rid="pone.0203030.ref031" ref-type="bibr">31</xref>], Hepatocellular Carcinoma cell line SK-Hep1/CDDP3-resistant to Cisplatin [<xref rid="pone.0203030.ref032" ref-type="bibr">32</xref>], and Colon Cancer cell lines SW-620-L-OHP and LoVo-L-OHP-resistant to Oxaliplatin [<xref rid="pone.0203030.ref033" ref-type="bibr">33</xref>]. Our simulation result mimics the average behavior of the resistant cancer cell lines over the time period of 5 days (<xref ref-type="fig" rid="pone.0203030.g002">Fig 2B</xref>), using the parameter set estimated through the MCMC method.</p><p>The model was simulated for a sufficiently long time to study the temporal evolution of the drug-sensitive and drug-resistant cancer cells without any therapeutic interventions (<xref ref-type="fig" rid="pone.0203030.g002">Fig 2C</xref>). Here, it was observed that during the early stages of tumor development, the stem cells (S) show a very slow rate of proliferation. According to our simulation results, it is observed that although a single stem cell initiates the formation of the entire tumor, the stem cells maintain a very low number during the first few months of tumor development. The rapid proliferation of the Cancer cells (C) during the early growth phase lead to their transformation to the resistant C<sub>R</sub> species that soon start proliferating rapidly, thereby giving rise to a tumor. At the end of the exponential growth phase, the cancer progression is impeded by the activated M1, T<sub>H1</sub> and Tc immune cells and the systems stay relatively stable for some time until the stem cells start proliferating exponentially and form the main bulk of the tumor. Our simulation results indicate that the first resistant stem cell of the tumor is detected at 400 days. Around 800 days the model reaches its steady state. The total tumor density at steady state can be estimated to be around 2.5x10<sup>10</sup> cells/ml, i.e. 25 times higher than the reported minimum threshold of a clinically detectable tumor [<xref rid="pone.0203030.ref003" ref-type="bibr">3</xref>]. From here we calculate the relative abundance of the sub-populations of the tumor cells and derive that at steady state, the tumor is composed of 94.59% Stem cells (S), 4.49% Cancer cells (C), 1% Cancer Resistant cells (C<sub>R</sub>) and small fraction of Stem Resistant cells (S<sub>R</sub>) that comprises 0.001% of the tumor mass.</p></sec><sec id="sec007"><title>4.1.2. Immune cell-ratio comparison with cytometric data</title><p>Our simulations results revealed the dynamics of the adaptive immune responses generated during the tumor development (<xref ref-type="fig" rid="pone.0203030.g002">Fig 2C</xref>). Here we observe that as the tumor sub-populations begins to proliferate, the Tc cells show enhanced activation that is required for the natural regression of the tumor (<xref ref-type="fig" rid="pone.0203030.g002">Fig 2C</xref>). However, as the tumor continues to proliferate and the resistant cancer cells (C<sub>R</sub>) peaks to 1.5x10<sup>9</sup> cells/ml, there is a sharp rise in the M1 and T<sub>H1</sub> cells proliferation. The combined effect of the Tc, M1 and T<sub>H1</sub> cells helps to impede the tumor development and decrease it by 3 folds which then falls below the limit of tumor detection (i.e. 10<sup>9</sup> cells/ml, [<xref rid="pone.0203030.ref003" ref-type="bibr">3</xref>]) and apparently stays dormant till 400 days. Thereafter, as the stem (S) and resistant stem (S<sub>R</sub>) cells start proliferating, the adaptive immunity becomes active again. However, this is also accompanied with the increase in abundance of M2 and Treg cells (<xref ref-type="fig" rid="pone.0203030.g002">Fig 2C</xref>), that helps in the sustenance and continued survival of the tumor cells.</p><p>In order to analyse the changes in the immune activation state before and after tumor formation, the immune cell ratio values obtained at the steady state are estimated and compared to the cell ratios in the normal disease-free condition (<xref ref-type="fig" rid="pone.0203030.g002">Fig 2F</xref>). It may be mentioned here, in <xref ref-type="fig" rid="pone.0203030.g002">Fig 2E and 2F</xref>, CD4 depicts the summation of both the T<sub>H1</sub> and T<sub>H2</sub> cells of our model, while CD8 implies Tc cells. From our model analysis, we observe that, during Cancer, the ratio of CD4 and CD8 cells reaches a mean value of 2.75, that is in sharp contrast to the normal healthy individuals which show a value of 1.48 (<xref ref-type="fig" rid="pone.0203030.g002">Fig 2F</xref>) [<xref rid="pone.0203030.ref034" ref-type="bibr">34</xref>]. On the other hand, the value of CD4:Treg ratio in Cancer shows a value of 15.2 that is higher than the ratio observed in the normal scenario. This happens due to the enhanced T<sub>H2</sub> proliferation during tumor development. This also explains the reason for the elevated CD4/Treg ratio. However, the CD8:Treg ratio shows a decrease in Cancer patients and reaches to about 5.5, which is a characteristic of resistant tumors in mammals [<xref rid="pone.0203030.ref035" ref-type="bibr">35</xref>]. In <xref ref-type="fig" rid="pone.0203030.g002">Fig 2E</xref> we have compared these results of our numerical simulation with experimental data obtained from various literatures. Here, we clearly observe that our simulation corroborates very well with the experimental observations made from blood samples of Cancer patients (<xref ref-type="fig" rid="pone.0203030.g002">Fig 2E</xref>) [<xref rid="pone.0203030.ref036" ref-type="bibr">36</xref>, <xref rid="pone.0203030.ref037" ref-type="bibr">37</xref>]. Additionally, we have observed the changes in the T<sub>H1</sub>:T<sub>H2</sub> and M1:M2 ratios that have important implications in Cancer prognosis. We find that both T<sub>H1</sub>:T<sub>H2</sub> ratio and M1:M2 ratio get decreased during Cancer as compared to the normal disease-free conditions (<xref ref-type="fig" rid="pone.0203030.g002">Fig 2F</xref>) [<xref rid="pone.0203030.ref038" ref-type="bibr">38</xref>, <xref rid="pone.0203030.ref039" ref-type="bibr">39</xref>]. These results are in excellent agreement to the literature that suggests Cancer patients showing T<sub>H1</sub>:T<sub>H2</sub> ratio below 8 show poor disease prognosis [<xref rid="pone.0203030.ref039" ref-type="bibr">39</xref>].</p></sec><sec id="sec008"><title>4.1.3. Cytokine production</title><p>IL10 production is a characteristic feature for Cancer detection. During Cancer, the marked increase in IL10 production has been noted in blood samples of various cancer patients, where an average concentration of 0.01ng/ml has been recorded in various protein expression studies [<xref rid="pone.0203030.ref040" ref-type="bibr">40</xref>&#x02013;<xref rid="pone.0203030.ref042" ref-type="bibr">42</xref>]. The temporal protein expression profile, from our simulations, suggests the IL10 expression starts increasing around the 15<sup>th</sup> day until it reaches to a concentration of 0.005 ng/ml (<xref ref-type="fig" rid="pone.0203030.g002">Fig 2D</xref>). The IFN-&#x003b3; production begins along with the proliferation of the Tc cells and increases sharply with the activation of the T<sub>H1</sub> cells (<xref ref-type="fig" rid="pone.0203030.g002">Fig 2D</xref>). This is accompanied by IL2 production that helps in the continued proliferation of the T<sub>H1</sub> cells. After the proliferation of the stem cells, the cytokine production increases further. The IL10 concentration starts increasing rapidly and attains a concentration of 0.009 ng/ml at steady state. The steady state concentrations of IFN-&#x003b3; and IL2 reach 9.6 ng/ml and 0.6 ng/ml respectively. The cytokine expression levels from our simulation lie close to the experimentally observed ranges of protein expression of cancer treatment prior to their treatment [<xref rid="pone.0203030.ref040" ref-type="bibr">40</xref>].</p></sec></sec><sec id="sec009"><title>4.2. Model analysis</title><sec id="sec010"><title>4.2.1. Development of drug resistance is governed by the pattern of stem cell differentiation</title><p>With the assumption that the stem cells predominantly tend to renew their pool of stem cells, i.e. with a probability p3, we have varied the values of p1 and p2 to observe the effect of the asymmetric and symmetric differentiation of the stem cell on the development of drug resistance (<xref ref-type="fig" rid="pone.0203030.g003">Fig 3A&#x02013;3D</xref>). Here it may be observed that as we increase the values of p1 and p2, the rate of the stem cell renewal decreases gradually, thereby leading to decrease in the steady state values of S and S<sub>R</sub> (<xref ref-type="fig" rid="pone.0203030.g003">Fig 3A and 3B</xref>). However, in the case of C cells (<xref ref-type="fig" rid="pone.0203030.g003">Fig 3C</xref>), we observe that as we increase the value of p1, the steady state values of C decreases, whereas the variation of p2 has little effect on the steady states of C (<xref ref-type="fig" rid="pone.0203030.g003">Fig 3C</xref>). The steady state level of C<sub>R</sub> on the other hand, is greatly influenced by p1 and p2 (<xref ref-type="fig" rid="pone.0203030.g003">Fig 3D</xref>). With the increase in the value of p1 and p2, the steady states value of C<sub>R</sub> increases, signifying as the mode of stem cell differentiation changes, the tumor cell sub-populations tend to transform into the resistant Cancer cells. Hence, from our results, we may infer that higher asymmetric stem cell division may be associated with a high rate of drug resistance.</p><fig id="pone.0203030.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0203030.g003</object-id><label>Fig 3</label><caption><title>Parameter variation study.</title><p>(a-d) Surface plot of the steady state values of S, S<sub>R</sub>, C and C<sub>R</sub> under varying p1 and p2; (e-h) Surface plot of the steady state values of S, S<sub>R</sub>, C and C<sub>R</sub> under varying &#x003b3;<sub>M1</sub> and &#x003b3;<sub>M2</sub>; (i) Temporal Plot at &#x003b2;<sub>Th1Ck2</sub> = 0.1; (j-k) Phase plane of S vs. IFN-&#x003b3; and C vs. IFN-&#x003b3; at &#x003b2;<sub>Th1Ck2</sub> = 0.1; (l) T<sub>H1</sub>/T<sub>H2</sub> ratio at varying &#x003bc;<sub>Th1Ck1</sub>; (m) Fold change in steady states at varying &#x003bc;<sub>Th1Ck1</sub>.</p></caption><graphic xlink:href="pone.0203030.g003"/></fig></sec><sec id="sec011"><title>4.2.2. Dual role of tumor associated macrophages</title><p>The differential regulatory behavior of the type I and type II TAMs on the tumor cells was studied by varying the &#x003b3;<sub>M1</sub> and &#x003b3;<sub>M2</sub> parameters, governing the growth rate of the M1 and M2 macrophages (<xref ref-type="fig" rid="pone.0203030.g003">Fig 3E&#x02013;3H</xref>). Here it was observed, as we increase the birth rate of M1, the steady state values of all the sub-populations of the tumor decreases. However, on varying &#x003b3;<sub>M2</sub>, we observe that although the S, S<sub>R</sub> and C sub-populations show a decrease in the steady state values, the C<sub>R</sub> population increases (<xref ref-type="fig" rid="pone.0203030.g003">Fig 3E&#x02013;3H</xref>). This result corroborates with the experimental observations that indicate that while M1 macrophages may a have an important role in suppression of the tumor growth, a higher abundance of M2 macrophages may lead to poor disease prognosis [<xref rid="pone.0203030.ref043" ref-type="bibr">43</xref>]. From our model analysis, we infer that a higher proliferation of M2 TAMs leads to an increased accumulation of resistant cancer cells in the tumor. This is primarily because of the feedback regulations that govern the dynamics of the tumor-immune interaction network.</p></sec><sec id="sec012"><title>4.2.3. IFN-gamma and IL10 feedbacks regulate Cancer progression</title><p>The cytokines are the key regulators of the Tumor-Immune interaction network. The IFN-&#x003b3; produced by the T<sub>H1</sub> cells helps in maintaining the steady state dynamics of the entire system. Parameter variation studies reveal that as we increase IFN-&#x003b3; production from the T<sub>H1</sub> cells by changing the value of &#x003b2;<sub>Th1Ck2</sub> between 10<sup>-7</sup> and 10<sup>-2</sup> ng/cell/day, the S and S<sub>R</sub> cells show a dampening oscillation in their temporal behavior and these stem cell populations gradually decrease to a very low value. On the other hand, with the increasing &#x003b2;<sub>Th1Ck2</sub> values, the temporal behavior of C and C<sub>R</sub> cell population changes from dampening to stable oscillations at &#x003b2;<sub>Th1Ck2</sub> = 0.1 (<xref ref-type="fig" rid="pone.0203030.g003">Fig 3I</xref>). The increased production of IFN-&#x003b3; leads to the rapid killing of the S and S<sub>R</sub> populations, whose oscillations dampen with time resulting in complete elimination of the stem cells from the system (<xref ref-type="fig" rid="pone.0203030.g003">Fig 3J</xref>). However, the high rate of C proliferation balances out the negative feedback effect of the high IFN-&#x003b3; production, which keeps oscillating the system (<xref ref-type="fig" rid="pone.0203030.g003">Fig 3K</xref>). The phase-plot depicts the feedback regulation that operates between the Cancer (C) cells and IFN-&#x003b3; that regulates the Cancer relapse. As the Cancer proliferation reaches 4x10<sup>6</sup> cells, the IFN-&#x003b3; production starts increasing which reduces the Cancer proliferation. When the Cancer cells fall below 1x10<sup>6</sup> cells, the IFN-&#x003b3; production also starts decreasing. However, at low levels IFN-&#x003b3;, the Cancer cells start proliferating again (<xref ref-type="fig" rid="pone.0203030.g003">Fig 3K</xref>). This leads the system into stable steady state oscillations.</p><p>Another important feedback regulation that is crucial for the determination of tumor progression is the negative feedback effect of the IL10 cytokine on the T<sub>H1</sub> proliferation. This is governed by the parameter &#x003bc;<sub>Th1Ck1</sub>. As the value of &#x003bc;<sub>Th1Ck1</sub> is increased, the T<sub>H1</sub>/T<sub>H2</sub> ratio decreased rapidly (<xref ref-type="fig" rid="pone.0203030.g003">Fig 3L</xref>). This results in the further proliferation of all the tumor sub-populations, i.e., S, S<sub>R</sub>, C and C<sub>R</sub>, and the fold changes in the steady state values of all four increases with increasing &#x003bc;<sub>Th1Ck1</sub> values (<xref ref-type="fig" rid="pone.0203030.g003">Fig 3M</xref>). Here it may be observed that inhibition of T<sub>H1</sub> cells by IL10, results in higher fold changes of the steady state of S<sub>R</sub> cells.</p></sec></sec><sec id="sec013"><title>4.3. Development of treatment strategies</title><sec id="sec014"><title>4.3.1. Failure of chemo and radiotherapies due to the presence of resistant cells</title><p>Chemotherapy and Radiotherapy are effective for controlling tumor proliferation in the absence of the resistant cells, i.e. when the rate of transformation of the stem and cancer cells to their resistant counterparts reduces. Here we have tried to simulate the cancer scenario without any mutational pressure, i.e. m<sub>C</sub> = 0 and m<sub>S</sub> = 0. Under such conditions, when we apply the Treatment Protocol 1, we observe the Stem and the Cancer cells population decreases rapidly and an overall reduction in the tumor population is observed (<xref ref-type="fig" rid="pone.0203030.g004">Fig 4</xref>). However, during the formation of a tumor, a certain fraction of the tumor cells acquire resistance to drugs. Under such conditions, i.e. m<sub>C</sub>&#x0003e;0 and m<sub>S</sub>&#x0003e;0, when the Treatment Protocol 1 is applied at the end of the detection time (DT = 200 days), we observe that even though the drug-sensitive populations <italic>viz</italic>. S and C decreases, the resistant populations S<sub>R</sub> and C<sub>R</sub> remain unaffected during the chemotherapeutic cycles. Thereafter, during the Radiotherapy cycles, the S<sub>R</sub> cell population being completely unaffected by radiation proliferates rapidly, while the C and C<sub>R</sub> population sharply decreases for some time and then becomes stable. In the next treatment-free stage, S<sub>R</sub>, C and C<sub>R</sub> start proliferating again. This activates the IFN-&#x003b3; from the T<sub>H1</sub> and Tc cells that help to bring down the S<sub>R</sub> and C<sub>R</sub> populations a little, that are then sustained at by the M2 and the Treg cells of the tumor microenvironment. The last phase of Chemotherapy does not have any effect on S<sub>R</sub> and C<sub>R</sub> populations. Hence the reduction in the overall tumor mass is not substantial. Also, it may be noticed here that at the end of this treatment regimen the T<sub>H1</sub>/T<sub>H2</sub> ratio is reduced to 2.5 that is indicative of poor disease prognosis.</p><fig id="pone.0203030.g004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0203030.g004</object-id><label>Fig 4</label><caption><title>Changes in the tumor growth after therapeutic interventions.</title><p>Protocol 1 has been applied without and with the presence of resistant cells. Protocol 2 efficiently suppresses tumor in spite of the presence of resistant cells. Color code: Black-without treatment, Green-Chemotherapy, Red-Radiotherapy, Pink-Immunotherapy.</p></caption><graphic xlink:href="pone.0203030.g004"/></fig></sec><sec id="sec015"><title>4.3.2. Immune interventions for effective tumor remission</title><p>Combinatorial treatment protocol was designed to reduce the tumor burden and restore healthy T<sub>H1</sub>/T<sub>H2</sub> ratio. Parameter variation studies revealed the importance of the T<sub>C</sub> and the T<sub>H1</sub> cells in the regulation of the steady state levels of the tumor cells. Here, Immunotherapy was introduced as two control variables, i.e., u3_Tc and u3_T<sub>H1</sub>, which boost the production of the T<sub>C</sub> and T<sub>H1</sub> respectively. The stimulus to the T<sub>H1</sub> and T<sub>C</sub> cells was started at the end of the last chemotherapeutic cycle and was administered for 20 days followed by 1 day rest. This was repeated for 10 cycles. The dosage of each therapy was varied in wide ranges, and it was observed that when Immunotherapy is low, the change in Radio and Chemotherapies does not affect the tumor population significantly which is reflected in the very small tumor fold change and low T<sub>H1</sub>/T<sub>H2</sub> ratio (<xref ref-type="supplementary-material" rid="pone.0203030.s002">S1 Fig</xref>). As the Immunotherapy is increased, the fold change of tumor population increases along with the T<sub>H1</sub>/T<sub>H2.</sub> However at very high doses of immunostimulation, the fold changes decreases and the T<sub>H1</sub>/T<sub>H2</sub> ratio increases abruptly that leads to extreme suppression of the T<sub>H2</sub> cells in the system. Hence the region 1.5&#x0003c; d<sub>I</sub> &#x0003c;2.5 can be considered as the ideal dosage of immunostimulation required for triggering the remission of Tumor. Using the leads from this analysis, the Protocol 2 was designed. At the end of this treatment regimen, it was observed that all the four tumor sub-populations showed a huge reduction in their proliferation, i.e. 136 fold reduction in tumor mass (Protocol 2). The T<sub>H1</sub>/T<sub>H2</sub> ratio was boosted to 8.8.</p></sec></sec></sec><sec id="sec016"><title>5. Discussion</title><p>The model developed here throws light into the development of a full grown tumor from a single cancer stem cell (S), and the influence of the tumor microenvironment during its maturation. The study of the temporal evolution of tumor development shows that although the cancer stem cell forms the &#x02018;seed&#x02019; from which the tumor emanate, the stem cell population remains low in the beginning. These cancer stem cells, owing to their slow replication, are intrinsically resistant to radiotherapy and are only partially sensitive to chemotherapy [<xref rid="pone.0203030.ref044" ref-type="bibr">44</xref>, <xref rid="pone.0203030.ref045" ref-type="bibr">45</xref>]. Additionally, the stem cell sub-populations have a strong immune-suppressive effect on the tumor microenvironment [<xref rid="pone.0203030.ref046" ref-type="bibr">46</xref>]. This phenomenon has been captured in our model in the study of the temporal evolution of the tumor-immune interaction dynamics, where we observe that coincident with the proliferation of the stem and resistant stem cell there is also an increased proliferation of the M2 and Treg cells (<xref ref-type="fig" rid="pone.0203030.g002">Fig 2C</xref>). This consequently leads to the lowering of the M1/M2 and T<sub>H1</sub>/T<sub>H2</sub> ratio that is associated with the formation of resistant tumors (<xref ref-type="fig" rid="pone.0203030.g002">Fig 2F</xref>). Moreover, it has been observed in our study that the proliferation of stem cell sub-populations leads to suppression of the Tc cells and the activation of the Treg cells, that results in the lowering the CD8/Treg ratio during Cancer (<xref ref-type="fig" rid="pone.0203030.g002">Fig 2F</xref>). This happens primarily because of the direct negative regulatory effects of the stem and resistant stem cells on the growth of the Tc cells. Hence, an early detection of the tumor is crucial for an effective treatment, when the stem cell population in the tumor remains low and the resistant stem cell population is not yet formed.</p><p>The model also captures the different patterns of CSC differentiation and its role in determining the fate of the tumor. Here, it has been observed that as the differentiation pattern of CSC shifts towards the asymmetric pattern, the CSC pool begins to deplete and the CSC starts producing the terminally differentiated cancer cells that have a finite lifespan. The reduction in the stem cell population helps in the reduction of its immune-suppressive effects on the Tc cells. At the same time, the differentiation of the stem into the cancer cells stimulates the Tc cells to get activated that now inhibit the tumor via the negative feedback regulation. However, the steady state value of the resistant cancer cells increases and overrides the negative feedback effect of the immune cells, reinforcing the observations that a higher asymmetric stem cell differentiation may be associated with the formation of more resistant tumors. Our model analysis also indicates that at low p<sub>1</sub> value, as the probability of symmetric differentiation (p<sub>2</sub>) of stem cells is increased, the steady state levels of stem cells rapidly decreases, however it has little effect on the steady state value of Cancer cells. On the contrary, at high p<sub>1</sub> value, the increase in p<sub>2</sub> leads to the transformation of the cancer to resistant cancer cells. These results signify that reduction in stem cell symmetric renewal (p3) of the cell leads to its differentiation into more resistant tumors.</p><p>The model further elucidates a dual role of the M2-TAMs in regulating the tumor formation (<xref ref-type="fig" rid="pone.0203030.g003">Fig 3E&#x02013;3H</xref>). Here we observe that on one hand, the M2-TAMs aid in the suppression of the S, S<sub>R</sub> and C cells of the tumor. This is because M2 is a prime source for the production of IL10 cytokine that has an important role in positively regulating the proliferation of the Cancer (C) cells. Hence, as the M2-TAMs increase in abundance, the cancer cells begin to proliferate via a positive feedback loop (<xref ref-type="fig" rid="pone.0203030.g005">Fig 5A</xref>). This leads to the activation of both the Tc and T<sub>H1</sub> cells that inhibits the tumor cells <italic>via</italic> their negative feedback by producing a higher amount of IFN-&#x003b3; and higher cytotoxic activity of the Tc cells (<xref ref-type="fig" rid="pone.0203030.g005">Fig 5A</xref>). However, on the other hand, it may be observed that M2-TAMs help in the growth of the C<sub>R</sub> cells via the positive feedback loop, while the negative feedback has little effect on the C<sub>R</sub> sub-population. This observation explains the reason for the refractory behavior of the tumor to treatment strategies under the presence of the M2-TAMs [<xref rid="pone.0203030.ref047" ref-type="bibr">47</xref>].</p><fig id="pone.0203030.g005" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0203030.g005</object-id><label>Fig 5</label><caption><title>Regulatory feedback loops.</title><p>(a) The M2 macrophage triggers two feedback loops. The first loop through IL10 is a positive feedback that triggers tumor proliferation. This, in turn, activates the second loop through IFN- &#x003b3; that inhibits the tumor; (b) The T<sub>H1</sub> derived IFN- &#x003b3; inhibits the tumor via a negative feedback that leads to an oscillation in the population of tumor cells; (c) The positive feedback loop through IL10 is responsible for the maintenance of tumor and suppression of T<sub>H1</sub>/ T<sub>H2</sub> ratio.</p></caption><graphic xlink:href="pone.0203030.g005"/></fig><p>Our study reveals the functional behavior of the feedback mechanisms that regulate the behavior of the entire tumor-immune interaction network. From our parameter variation studies, the importance of the IFN-&#x003b3; production in regulating the temporal behavior of the tumor development is observed. Here, we found that as the rate of IFN-&#x003b3; production from the T<sub>H1</sub> cells increases, the negative feedback effect of IFN-&#x003b3; on the tumor helps in the suppression of the tumor cells (Figs <xref ref-type="fig" rid="pone.0203030.g003">3I</xref> and <xref ref-type="fig" rid="pone.0203030.g005">5B</xref>). However, the replicative potential of the Cancer and resistant Cancer balances out the negative effect of the IFN-&#x003b3; leading to an oscillatory tumor-relapsing behavior, whereas the slowly replicating stem and resistant cells sub-populations gradually get eliminated from the tumor due to the high production of the IFN-&#x003b3; cytokine (<xref ref-type="fig" rid="pone.0203030.g003">Fig 3J and 3K</xref>). This finding has important implications in the design of Immunotherapeutic protocols, where we observe the differential behavior of the tumor cells in response to high IFN-&#x003b3; production. Using our model, we further explore the effects of the negative feedback of the IL10 cytokine on the T<sub>H1</sub> cells (Figs <xref ref-type="fig" rid="pone.0203030.g003">3L, 3M</xref> and <xref ref-type="fig" rid="pone.0203030.g005">5C</xref>). We also make an important observation, where we find that as the sensitivity of T<sub>H1</sub> cells to IL10 increases, the T<sub>H1</sub>/T<sub>H2</sub> ratio decreases sharply. This leads to the increased proliferation of the tumor cells. The fold change in the steady values of the resistant stem cells is the greatest signifying the prognostic role of the T<sub>H1</sub>/T<sub>H2</sub> ratio in predicting tumor progression and the formation of a resistant tumor with higher proportion of resistant stem cells.</p><p>With the knowledge of the regulatory mechanisms governing the differential response of the tumor sub-populations to the microenvironment, we have tried to explore the effect of treatment strategies conventionally adopted for the treatment of Cancer (<xref ref-type="fig" rid="pone.0203030.g004">Fig 4</xref>). Using our model we have been able to show that the reason for the failure of conventional Chemotherapy and Radiotherapy is primarily due to the formation of the resistant cancer stem cells S<sub>R</sub> and resistant cancer cells C<sub>R</sub> within the tumor. Under the conditions where there are no mutations conferring drug resistivity to the tumor, a significant reduction in tumor mass may be achieved using Chemo and Radio therapy alone. However, in reality, a small population of resistant tumor cells exists in the tumor that remains refractory to these treatment protocols. In order to successfully remove the tumor, a combination of the conventional treatment protocol along with Immuno-therapy can help alleviate the disease scenario. There can be several ways of boosting the immune system. However, in this work, we propose that a synergistic stimulus to both T<sub>H1</sub> and Tc cells is required for the generation of an adaptive immune response that is capable of reducing both the drug-sensitive as well as the drug-resistant sub-populations of the tumor. In order to achieve this, dosage of Radio, Chemo and Immunotherapies were varied to create 1000 different treatment combinations and thereafter a treatment protocol (Protocol 2) has been designed to ensure maximal reduction in the tumor mass, as well as the restoration of a healthy T<sub>H1</sub>/T<sub>H2</sub> balance.</p><p>In this model, we try to capture the high complexity of the tumor microenvironment with a simple ODE model that represents the interaction of the tumor cell sub-populations and the immune cells at the phenotypic level. Here we assume that the parameters governing these cellular interactions are a cumulative outcome of the various molecular and the intracellular signalling events occurring in the microenvironment that influence the immune evasion but have not been explicitly considered in this model for its simplification. However, it is worth mentioning that depending on the availability of data and hybrid modeling techniques involving a combination of different mathematical tools and strategies, this model may further be improvised by considering the effect of the various molecular events such as angiogenesis, the role of the miRNA, exosomes and chemokines in mediating the cellular interactions, the metabolic pathways as well as the hypoxic conditions [<xref rid="pone.0203030.ref048" ref-type="bibr">48</xref>], that may further help us unravel unknown regulations underlying the tumor immune interaction and the development of drug-resistance.</p></sec><sec id="sec017"><title>6. Conclusion</title><p>With respect to the long standing &#x02018;seed and soil&#x02019; hypothesis, we propose a model that throws light into the previously unexplored regulations governing tumor-immune interaction. This novel approach of developing of a tumor-immune interaction model considering both the stem cell differentiation pattern as well as the effect of the microenvironment has helped us in unveiling the effect of stem cell differentiation on the development of drug resistance and the different mechanistic regulations governing the tumor-immune interaction dynamics. However, this model does not capture the diffusion kinetics of the cytokines or the time delay associated with the cytokine regulations. Nonetheless, the observations derived from the model have been corroborated extensively with the experimental observations in cytometric and protein expression studies that strengthen the reliability of our model for the prediction of mechanistic regulations of tumor-immune interaction and design of the treatment protocols. This study can further be used to optimize treatment strategies, drug dosage and time schedules for designing advanced treatment protocols for Cancer.</p></sec><sec id="sec018"><title>7. Methods</title><sec id="sec019"><title>7.1. Model development</title><sec id="sec020"><title>7.1.1. Tumor formation</title><p>The core tumor consists of the Cancer Stem Cells (S), the Cancer Cells (C) and their drug resistant counterparts Resistant Stem Cells (S<sub>R</sub>) and Resistant Cancer Cells (C<sub>R</sub>) (<xref ref-type="fig" rid="pone.0203030.g001">Fig 1A</xref>, red box). The model takes into consideration the different patterns of stem cell differentiation, <italic>viz</italic>. the symmetric and asymmetric stem cell differentiation (<xref ref-type="fig" rid="pone.0203030.g001">Fig 1B</xref>). In the asymmetric differentiation, one stem cell (S) produces one daughter stem cell (S) and a differentiated progenitor Cancer cell (C) with probability p<sub>1</sub>, while in the symmetric differentiation one stem cell (S) produce either two Cancer cells (C) with probability p<sub>2</sub> or two stem cells (S) with probability p<sub>3</sub> (where, p<sub>1</sub>+p<sub>2</sub>+p<sub>3</sub> = 1). The stem cells undergoing asymmetric differentiation acquire mutation (represented with black dotted line in <xref ref-type="fig" rid="pone.0203030.g001">Fig 1A</xref>) with a probability m<sub>S</sub> that leads to the transformation of a stem cell (S) to a resistant stem cell (S<sub>R</sub>). Since the probability that this mutation hits the daughter stem cell and not the differentiated cancer cell is 0.5, the probability of formation of S<sub>R</sub> from S is further multiplied by p<sub>1</sub>/2. The symmetric differentiation leads to the renewal of the non-mutant stem cell (S) pool with a probability (1-m<sub>S</sub>)(1-p<sub>1</sub>-p<sub>2</sub>) [<xref rid="pone.0203030.ref003" ref-type="bibr">3</xref>]. Considering these factors (as described by Tomasetti and Levy [<xref rid="pone.0203030.ref003" ref-type="bibr">3</xref>]), we assume that the growth rate of S can be mathematically represented as (&#x003b3;<sub>S</sub>(1 &#x02212; m<sub>S</sub>)(1 &#x02212; p<sub>1</sub> &#x02212; p<sub>2</sub>))S, while the rate of depletion of the stem cell pool, that includes the differentiation of S to C and the transformation S to S<sub>R</sub> can be represented as <inline-formula id="pone.0203030.e001"><alternatives><graphic xlink:href="pone.0203030.e001.jpg" id="pone.0203030.e001g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M1"><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">&#x003b4;</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">S</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">p</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>*</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">&#x003b3;</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">S</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">&#x003b3;</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">S</mml:mi></mml:mrow></mml:msub><mml:mo>*</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">m</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">S</mml:mi></mml:mrow></mml:msub><mml:mo>*</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">p</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:mfrac><mml:mo>)</mml:mo></mml:mrow><mml:mi mathvariant="normal">S</mml:mi></mml:math></alternatives></inline-formula>. It may be mentioned here that &#x003b3;<sub>S</sub> and &#x003b4;<sub>S</sub> represents that natural birth and death rates of S cells. A similar nomenclature has been followed for all the other cell types.</p><p>The resistant stem cells are formed from the transformation of an S to S<sub>R</sub>. The S<sub>R</sub> follows a similar pattern of self-renewal and differentiation that leads to the replenishment of the S<sub>R</sub> pool and the formation of differentiated C<sub>R</sub> cells [<xref rid="pone.0203030.ref003" ref-type="bibr">3</xref>]. Here, it may be assumed that the S<sub>R</sub> represents the compartment of stem cells that accumulate all the mutations in its pool, such that no separate compartment for any secondary mutations has been considered here in this model.</p><p>The Cancer cells (C) are formed from the stem cells (S) with the probability p<sub>1</sub>+p<sub>2</sub>. These C cells follow a Gompertzian growth kinetics that can be mathematically represented by <inline-formula id="pone.0203030.e002"><alternatives><graphic xlink:href="pone.0203030.e002.jpg" id="pone.0203030.e002g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M2"><mml:msub><mml:mrow><mml:mi mathvariant="normal">&#x003b3;</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">C</mml:mi></mml:mrow></mml:msub><mml:mo>*</mml:mo><mml:mrow><mml:mrow><mml:mi mathvariant="normal">log</mml:mi></mml:mrow><mml:mspace width="0.25em"/><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">C</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">x</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi mathvariant="normal">C</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">r</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula>, where C<sub>max</sub> is the carrying capacity of the tumor [<xref rid="pone.0203030.ref049" ref-type="bibr">49</xref>]. Here, it has been assumed that during proliferation these C cells acquire mutations with a probability m<sub>C</sub> and get transformed into C<sub>R</sub> cells. Hence the probability of proliferation of the non-mutant C cell is further multiplied by a factor (1-m<sub>C</sub>). The C<sub>R</sub> cells are formed from the differentiation of the S<sub>R</sub> cells with probability p<sub>1</sub>+p<sub>2</sub> and the transformation of the C to C<sub>R</sub> cells with probability m<sub>C</sub>. The C<sub>R</sub> cells also follow similar Gompertzian growth kinetics. The total carrying capacity of these non-stem tumor cells has been considered as K<sub>tumor</sub>, while each of C and C<sub>R</sub> has a carrying capacity of K<sub>tumor</sub>/2, so that both the cell populations can use the nutrients equally and have an equal advantage in proliferation.</p></sec><sec id="sec021"><title>7.1.2. Immune cells in the tumor microenvironment</title><p>As the tumor develops the resident TAMs, both M1 and M2, encounters the C and C<sub>R</sub> cells of the tumor and gets activated (<xref ref-type="fig" rid="pone.0203030.g001">Fig 1A</xref>) [<xref rid="pone.0203030.ref038" ref-type="bibr">38</xref>]. It may be assumed that this cell to cell interaction will follow a saturating kinetics where even in the presence of a high number of tumor cells, the availability of TAMs acts as the limiting condition. Hence a Michaelis-Menten type functional form may be used to represent the TAM activation, e.g. <inline-formula id="pone.0203030.e003"><alternatives><graphic xlink:href="pone.0203030.e003.jpg" id="pone.0203030.e003g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M3"><mml:msub><mml:mrow><mml:mi>&#x003b3;</mml:mi></mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>*</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>M</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>*</mml:mo><mml:mo>(</mml:mo><mml:mi>C</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>M</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>&#x003bb;</mml:mi></mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>)</mml:mo></mml:mrow></mml:math></alternatives></inline-formula>. These M1 and M2 TAMs now activate the T<sub>H1</sub> and T<sub>H2</sub> cells respectively [<xref rid="pone.0203030.ref050" ref-type="bibr">50</xref>]. Here the abundance of the T<sub>H</sub> cells acts as the limiting condition. In a similar way, the M2-TAMs also activate the Treg cells present in the tumor microenvironment [<xref rid="pone.0203030.ref051" ref-type="bibr">51</xref>]. The Tc cells, on the other hand, infiltrate the tumor, gets directly activated by C and C<sub>R</sub> cells (<xref ref-type="fig" rid="pone.0203030.g001">Fig 1A</xref>). However, the S and S<sub>R</sub> cells of the tumor inhibit the Tc cell proliferation [<xref rid="pone.0203030.ref009" ref-type="bibr">9</xref>]. This is a bidirectional reaction, as the activated Tc also tries to kill the tumor cell sub-populations via its cytotoxic activity [<xref rid="pone.0203030.ref052" ref-type="bibr">52</xref>, <xref rid="pone.0203030.ref053" ref-type="bibr">53</xref>]. The Treg cells act as immune-suppressor of the system and try to inhibit Tc proliferation, whereas the T<sub>H1</sub> cells act as immune-stimulator of the system that helps in Tc proliferation and tumor infiltration [<xref rid="pone.0203030.ref054" ref-type="bibr">54</xref>, <xref rid="pone.0203030.ref055" ref-type="bibr">55</xref>]. All these cell to cell interactions tend to follow saturation growth kinetics and hence have been modelled using the Michaelis Menten form discussed earlier [<xref rid="pone.0203030.ref023" ref-type="bibr">23</xref>].</p></sec><sec id="sec022"><title>7.1.3. Cytokines and feedbacks</title><p>Tumor formation triggers the immune system to produce cytokines. In this model, three important cytokines have been considered, <italic>viz</italic>. IFN-&#x003b3;, IL-2 and IL-10 (<xref ref-type="fig" rid="pone.0203030.g001">Fig 1A</xref>). The activation of the T<sub>H1</sub> cells stimulates the production of IL-2 cytokine from them. The amount of cytokine produced is directly proportional to the abundance of effector cells activated. Hence, this has been modelled using the Law of Mass Action, e.g. (<italic>&#x003b2;</italic><sub><italic>Th</italic>1<italic>CK</italic>3</sub> * <italic>T</italic><sub><italic>H</italic>1)</sub>, where &#x003b2;<sub>Th1CK3</sub> (units: ng cell<sup>-1</sup>day<sup>-1</sup>) is the rate of production of IL2 from T<sub>H1</sub> cells [<xref rid="pone.0203030.ref056" ref-type="bibr">56</xref>]. This IL2 is responsible for the auto-regulation and sustained proliferation of the T<sub>H1</sub> cells. Hence, we have considered a positive feedback loop from IL-2 to T<sub>H1</sub> cell that has been modelled using a saturating function <inline-formula id="pone.0203030.e004"><alternatives><graphic xlink:href="pone.0203030.e004.jpg" id="pone.0203030.e004g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M4"><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>&#x003bc;</mml:mi></mml:mrow><mml:mrow><mml:mi>T</mml:mi><mml:mi>h</mml:mi><mml:mn>1</mml:mn><mml:mi>C</mml:mi><mml:mi>k</mml:mi><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>*</mml:mo><mml:mi>I</mml:mi><mml:mi>L</mml:mi><mml:mn>2</mml:mn><mml:mo>*</mml:mo><mml:msub><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mi>H</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi>I</mml:mi><mml:mi>L</mml:mi><mml:mn>2</mml:mn><mml:mo>+</mml:mo><mml:mi>k</mml:mi><mml:mn>9</mml:mn></mml:mrow></mml:mfrac></mml:math></alternatives></inline-formula>, where the cytokine acts as the limiting factor [<xref rid="pone.0203030.ref023" ref-type="bibr">23</xref>, <xref rid="pone.0203030.ref056" ref-type="bibr">56</xref>]. Similarly, the IFN-&#x003b3; is produced by T<sub>H1</sub> and Tc cells which have a negative feedback effect on all the tumor cell sub-populations. The production of IL-10 is regulated by M2, Treg and T<sub>H2</sub> cells. An auto-regulatory positive feedback loop exists between IL10 and the Treg cells. IL10 also plays an important role in the proliferation of the C and C<sub>R</sub> cells and inhibition of the T<sub>H1</sub> cells. This IL10 mediated regulation captures the inhibitory actions of T<sub>H2</sub> on T<sub>H1</sub> cells that are often observed in Cancer scenario.</p></sec></sec><sec id="sec023"><title>7.2. Model equations</title><p>Based on the biological relevance and mathematical assumptions discussed above, the equations representing the tumor-immune interaction network comprising of 13 Ordinary Differential Equations (Eqs <xref ref-type="disp-formula" rid="pone.0203030.e005">1</xref>&#x02013;<xref ref-type="disp-formula" rid="pone.0203030.e017">13</xref>) and 71 parameters have been enlisted below:
<disp-formula id="pone.0203030.e005"><alternatives><graphic xlink:href="pone.0203030.e005.jpg" id="pone.0203030.e005g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M5"><mml:mrow><mml:mo>&#x02022;</mml:mo><mml:mspace width="0.50em"/><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">dS</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">dt</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi mathvariant="normal">&#x003b3;</mml:mi><mml:mi mathvariant="normal">S</mml:mi></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">S</mml:mi></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mi mathvariant="normal">p</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mi mathvariant="normal">p</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi mathvariant="normal">S</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">&#x003b4;</mml:mi></mml:mrow><mml:mi mathvariant="normal">S</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi mathvariant="normal">p</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:msub><mml:mrow><mml:mo>*</mml:mo><mml:mi mathvariant="normal">&#x003b3;</mml:mi></mml:mrow><mml:mi mathvariant="normal">S</mml:mi></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:msub><mml:mi mathvariant="normal">&#x003b3;</mml:mi><mml:mi mathvariant="normal">S</mml:mi></mml:msub><mml:mo>*</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">S</mml:mi></mml:msub><mml:msub><mml:mrow><mml:mo>*</mml:mo><mml:mi mathvariant="normal">p</mml:mi></mml:mrow><mml:mn>1</mml:mn></mml:msub></mml:mrow><mml:mn>2</mml:mn></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">S</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:msub><mml:mi mathvariant="normal">&#x003bc;</mml:mi><mml:mi mathvariant="normal">S</mml:mi></mml:msub><mml:mo>*</mml:mo><mml:mi mathvariant="normal">S</mml:mi><mml:mo>*</mml:mo><mml:mi mathvariant="normal">IFN</mml:mi><mml:mi mathvariant="normal">&#x003b3;</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">k</mml:mi></mml:mrow><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:mi mathvariant="normal">IFN</mml:mi><mml:mi mathvariant="normal">&#x003b3;</mml:mi></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>&#x02013;</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">tck</mml:mi><mml:mo>*</mml:mo><mml:mi mathvariant="normal">S</mml:mi><mml:mo>*</mml:mo><mml:mi mathvariant="normal">Tc</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">ktc</mml:mi><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi mathvariant="normal">Tc</mml:mi></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives><label>(Eq 1)</label></disp-formula>
<disp-formula id="pone.0203030.e006"><alternatives><graphic xlink:href="pone.0203030.e006.jpg" id="pone.0203030.e006g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M6"><mml:mrow><mml:mo>&#x02022;</mml:mo><mml:mspace width="0.50em"/><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">dS</mml:mi></mml:mrow><mml:mi mathvariant="normal">R</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:mi mathvariant="normal">dt</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi mathvariant="normal">&#x003b3;</mml:mi><mml:mi mathvariant="normal">S</mml:mi></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">p</mml:mi></mml:mrow><mml:mn>1</mml:mn></mml:msub><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mi mathvariant="normal">p</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>&#x02212;</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">&#x003b4;</mml:mi></mml:mrow><mml:mi mathvariant="normal">S</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi mathvariant="normal">p</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:msub><mml:mrow><mml:mo>*</mml:mo><mml:mi mathvariant="normal">&#x003b3;</mml:mi></mml:mrow><mml:mi mathvariant="normal">S</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mspace width="0.25em"/><mml:msub><mml:mrow><mml:mi mathvariant="normal">S</mml:mi></mml:mrow><mml:mi mathvariant="normal">R</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">m</mml:mi></mml:mrow><mml:mi mathvariant="normal">S</mml:mi></mml:msub><mml:msub><mml:mrow><mml:mo>*</mml:mo><mml:mi mathvariant="normal">&#x003b3;</mml:mi></mml:mrow><mml:mi mathvariant="normal">S</mml:mi></mml:msub><mml:mo>*</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>&#x02212;</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi mathvariant="normal">p</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow><mml:mn>2</mml:mn></mml:mfrac><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mi mathvariant="normal">p</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">S</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:msub><mml:mi mathvariant="normal">&#x003bc;</mml:mi><mml:mrow><mml:mi mathvariant="normal">SR</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mo>*</mml:mo><mml:mi mathvariant="normal">S</mml:mi></mml:mrow><mml:mi mathvariant="normal">R</mml:mi></mml:msub><mml:mo>*</mml:mo><mml:mi mathvariant="normal">IFN</mml:mi><mml:mi mathvariant="normal">&#x003b3;</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="normal">k</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:mi mathvariant="normal">IFN</mml:mi><mml:mi mathvariant="normal">&#x003b3;</mml:mi></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>&#x02013;</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">tck</mml:mi><mml:mo>*</mml:mo><mml:mi mathvariant="normal">Sr</mml:mi><mml:mo>*</mml:mo><mml:mi mathvariant="normal">Tc</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">ktc</mml:mi><mml:mn>2</mml:mn><mml:mo>+</mml:mo><mml:mi mathvariant="normal">Tc</mml:mi></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives><label>(Eq 2)</label></disp-formula>
<disp-formula id="pone.0203030.e007"><alternatives><graphic xlink:href="pone.0203030.e007.jpg" id="pone.0203030.e007g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M7"><mml:mrow><mml:mo>&#x02022;</mml:mo><mml:mspace width="0.50em"/><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">dC</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">dt</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">&#x003b3;</mml:mi></mml:mrow><mml:mi mathvariant="normal">C</mml:mi></mml:msub><mml:mo>*</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">C</mml:mi></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>*</mml:mo><mml:mi>log</mml:mi><mml:mspace width="0.25em"/><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:mn>0.5</mml:mn><mml:mo>*</mml:mo><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>t</mml:mi><mml:mi>u</mml:mi><mml:mi>m</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi>C</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>r</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>*</mml:mo><mml:mi mathvariant="normal">C</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">&#x003b3;</mml:mi></mml:mrow><mml:mi mathvariant="normal">S</mml:mi></mml:msub><mml:mo>*</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi mathvariant="normal">p</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">p</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>*</mml:mo><mml:mi mathvariant="normal">S</mml:mi><mml:mo>&#x02013;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">&#x003b4;</mml:mi></mml:mrow><mml:mi mathvariant="normal">C</mml:mi></mml:msub><mml:mo>*</mml:mo><mml:mi mathvariant="normal">C</mml:mi><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">m</mml:mi></mml:mrow><mml:mi mathvariant="normal">C</mml:mi></mml:msub><mml:msub><mml:mrow><mml:mo>*</mml:mo><mml:mi mathvariant="normal">&#x003b3;</mml:mi></mml:mrow><mml:mi mathvariant="normal">C</mml:mi></mml:msub><mml:mo>*</mml:mo><mml:mi mathvariant="normal">C</mml:mi><mml:mo>+</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:msub><mml:mi mathvariant="normal">&#x003bc;</mml:mi><mml:mrow><mml:mi mathvariant="normal">C</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>*</mml:mo><mml:mi mathvariant="normal">C</mml:mi><mml:mo>*</mml:mo><mml:mi mathvariant="normal">IL</mml:mi><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mi mathvariant="normal">IL</mml:mi><mml:mn>10</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi mathvariant="normal">k</mml:mi><mml:mn>3</mml:mn></mml:msub></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>&#x02212;</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:msub><mml:mi mathvariant="normal">&#x003bc;</mml:mi><mml:mrow><mml:mi mathvariant="normal">C</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>*</mml:mo><mml:mi mathvariant="normal">C</mml:mi><mml:mo>*</mml:mo><mml:mi mathvariant="normal">IFN</mml:mi><mml:mi mathvariant="normal">&#x003b3;</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">IFN</mml:mi><mml:mi mathvariant="normal">&#x003b3;</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi mathvariant="normal">k</mml:mi><mml:mn>4</mml:mn></mml:msub></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>&#x02013;</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">tck</mml:mi><mml:mo>*</mml:mo><mml:mi mathvariant="normal">C</mml:mi><mml:mo>*</mml:mo><mml:mi mathvariant="normal">Tc</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">ktc</mml:mi><mml:mn>3</mml:mn><mml:mo>+</mml:mo><mml:mi mathvariant="normal">Tc</mml:mi></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives><label>(Eq 3)</label></disp-formula>
<disp-formula id="pone.0203030.e008"><alternatives><graphic xlink:href="pone.0203030.e008.jpg" id="pone.0203030.e008g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M8"><mml:mrow><mml:mo>&#x02022;</mml:mo><mml:mspace width="0.50em"/><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>C</mml:mi><mml:mi>R</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>&#x003b3;</mml:mi><mml:mi>C</mml:mi></mml:msub><mml:mo>*</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>R</mml:mi></mml:msub><mml:mo>*</mml:mo><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>g</mml:mi><mml:mspace width="0.25em"/><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:mn>0.5</mml:mn><mml:mo>*</mml:mo><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>t</mml:mi><mml:mi>u</mml:mi><mml:mi>m</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mi>R</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>r</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b3;</mml:mi><mml:mi>S</mml:mi></mml:msub><mml:mo>*</mml:mo><mml:msub><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:msub><mml:mo>*</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:msub><mml:mi>m</mml:mi><mml:mi>C</mml:mi></mml:msub><mml:mo>*</mml:mo><mml:msub><mml:mi>&#x003b3;</mml:mi><mml:mi>C</mml:mi></mml:msub><mml:mo>*</mml:mo><mml:mi>C</mml:mi><mml:mo>&#x02013;</mml:mo><mml:msub><mml:mi>&#x003b4;</mml:mi><mml:mrow><mml:mi>C</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:mo>*</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>R</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:msub><mml:mi>&#x003bc;</mml:mi><mml:mrow><mml:mi>C</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>*</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>R</mml:mi></mml:msub><mml:mo>*</mml:mo><mml:mi>I</mml:mi><mml:mi>L</mml:mi><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mi>I</mml:mi><mml:mi>L</mml:mi><mml:mn>10</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mn>5</mml:mn></mml:msub></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>&#x02212;</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:msub><mml:mi>&#x003bc;</mml:mi><mml:mrow><mml:mi>C</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>*</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>R</mml:mi></mml:msub><mml:mo>*</mml:mo><mml:mi>I</mml:mi><mml:mi>F</mml:mi><mml:mi>N</mml:mi><mml:mi>&#x003b3;</mml:mi></mml:mrow><mml:mrow><mml:mi>I</mml:mi><mml:mi>F</mml:mi><mml:mi>N</mml:mi><mml:mi>g</mml:mi><mml:mi>a</mml:mi><mml:mi>m</mml:mi><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mn>6</mml:mn></mml:msub></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>&#x02013;</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:mi>t</mml:mi><mml:mi>c</mml:mi><mml:mi>k</mml:mi><mml:mo>*</mml:mo><mml:mi>C</mml:mi><mml:mi>r</mml:mi><mml:mo>*</mml:mo><mml:mi>T</mml:mi><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mi>t</mml:mi><mml:mi>c</mml:mi><mml:mn>4</mml:mn><mml:mo>+</mml:mo><mml:mi>T</mml:mi><mml:mi>c</mml:mi></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives><label>(Eq 4)</label></disp-formula>
<disp-formula id="pone.0203030.e009"><alternatives><graphic xlink:href="pone.0203030.e009.jpg" id="pone.0203030.e009g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M9"><mml:mrow><mml:mo>&#x02022;</mml:mo><mml:mspace width="0.50em"/><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>M</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>&#x003b3;</mml:mi><mml:mrow><mml:mi>M</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>*</mml:mo><mml:msub><mml:mi>M</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>*</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:mi>C</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>R</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>M</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003bb;</mml:mi><mml:mrow><mml:mi>M</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>&#x02013;</mml:mo><mml:msub><mml:mi>&#x003b4;</mml:mi><mml:mrow><mml:mi>M</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>*</mml:mo><mml:msub><mml:mi>M</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:msub><mml:mi>&#x003bc;</mml:mi><mml:mrow><mml:mi>M</mml:mi><mml:mn>1</mml:mn><mml:mi>C</mml:mi><mml:mi>k</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>*</mml:mo><mml:mi>M</mml:mi><mml:mn>1</mml:mn><mml:mo>*</mml:mo><mml:mi>I</mml:mi><mml:mi>F</mml:mi><mml:mi>N</mml:mi><mml:mi>&#x003b3;</mml:mi></mml:mrow><mml:mrow><mml:mi>I</mml:mi><mml:mi>F</mml:mi><mml:mi>N</mml:mi><mml:mi>&#x003b3;</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mn>7</mml:mn></mml:msub></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives><label>(Eq 5)</label></disp-formula>
<disp-formula id="pone.0203030.e010"><alternatives><graphic xlink:href="pone.0203030.e010.jpg" id="pone.0203030.e010g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M10"><mml:mrow><mml:mo>&#x02022;</mml:mo><mml:mspace width="0.50em"/><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>M</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>&#x003b3;</mml:mi><mml:mrow><mml:mi>M</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>*</mml:mo><mml:msub><mml:mi>M</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>*</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:mi>C</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>R</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>M</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003bb;</mml:mi><mml:mrow><mml:mi>M</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mi>&#x003b4;</mml:mi><mml:mrow><mml:mi>M</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>*</mml:mo><mml:msub><mml:mi>M</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:msub><mml:mi>&#x003bc;</mml:mi><mml:mrow><mml:mi>M</mml:mi><mml:mn>2</mml:mn><mml:mi>C</mml:mi><mml:mi>k</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>*</mml:mo><mml:mi>M</mml:mi><mml:mn>2</mml:mn><mml:mo>*</mml:mo><mml:mi>I</mml:mi><mml:mi>L</mml:mi><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mi>I</mml:mi><mml:mi>L</mml:mi><mml:mn>10</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mn>10</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives><label>(Eq 6)</label></disp-formula>
<disp-formula id="pone.0203030.e011"><alternatives><graphic xlink:href="pone.0203030.e011.jpg" id="pone.0203030.e011g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M11"><mml:mrow><mml:mo>&#x02022;</mml:mo><mml:mspace width="0.50em"/><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mi>H</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>&#x003b3;</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:mi>H</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>*</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mi>H</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>*</mml:mo><mml:msub><mml:mi>M</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>&#x003bb;</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:mi>H</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mi>H</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>&#x02013;</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>&#x003b4;</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:mi>H</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>*</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mi>H</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>&#x02013;</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>&#x003bc;</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:mi>H</mml:mi><mml:mn>1</mml:mn><mml:mi>C</mml:mi><mml:mi>k</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>*</mml:mo><mml:mi>I</mml:mi><mml:mi>L</mml:mi><mml:mn>10</mml:mn><mml:mo>*</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mi>H</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi>I</mml:mi><mml:mi>L</mml:mi><mml:mn>10</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mn>8</mml:mn></mml:msub></mml:mrow></mml:mfrac><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>&#x003bc;</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:mi>h</mml:mi><mml:mn>1</mml:mn><mml:mi>C</mml:mi><mml:mi>k</mml:mi><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>*</mml:mo><mml:mi>I</mml:mi><mml:mi>L</mml:mi><mml:mn>2</mml:mn><mml:mo>*</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mi>H</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi>I</mml:mi><mml:mi>L</mml:mi><mml:mn>2</mml:mn><mml:mo>+</mml:mo><mml:mi>k</mml:mi><mml:mn>9</mml:mn></mml:mrow></mml:mfrac></mml:mrow></mml:math></alternatives><label>(Eq 7)</label></disp-formula>
<disp-formula id="pone.0203030.e012"><alternatives><graphic xlink:href="pone.0203030.e012.jpg" id="pone.0203030.e012g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M12"><mml:mrow><mml:mo>&#x02022;</mml:mo><mml:mspace width="0.50em"/><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mi>H</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>&#x003b3;</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:mi>H</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>*</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mi>H</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>*</mml:mo><mml:msub><mml:mi>M</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>&#x003bb;</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:mi>H</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mi>H</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>&#x02013;</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>&#x003b4;</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:mi>H</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>*</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mi>H</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives><label>(Eq 8)</label></disp-formula>
<disp-formula id="pone.0203030.e013"><alternatives><graphic xlink:href="pone.0203030.e013.jpg" id="pone.0203030.e013g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M13"><mml:mrow><mml:mo>&#x02022;</mml:mo><mml:mspace width="0.50em"/><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>T</mml:mi><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>&#x003b3;</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:mi>c</mml:mi></mml:mrow></mml:msub><mml:mo>*</mml:mo><mml:mi>T</mml:mi><mml:mi>c</mml:mi><mml:mo>*</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:mi>C</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>R</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:mi>T</mml:mi><mml:mi>c</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003bb;</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:mi>c</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b3;</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:mi>c</mml:mi></mml:mrow></mml:msub><mml:mo>*</mml:mo><mml:mfrac><mml:mrow><mml:mi>T</mml:mi><mml:mi>c</mml:mi><mml:mo>*</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mi>H</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi>T</mml:mi><mml:mi>c</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003bb;</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:mi>c</mml:mi><mml:mn>4</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mi>&#x003bc;</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:mi>c</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mo>*</mml:mo><mml:mi>T</mml:mi><mml:mi>c</mml:mi><mml:mo>*</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:mi>S</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>S</mml:mi><mml:mi>R</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:mi>T</mml:mi><mml:mi>c</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003bb;</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:mi>c</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>&#x02013;</mml:mo><mml:msub><mml:mi>&#x003b4;</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:mi>c</mml:mi></mml:mrow></mml:msub><mml:mo>*</mml:mo><mml:mi>T</mml:mi><mml:mi>c</mml:mi><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mi>&#x003bc;</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:mi>c</mml:mi><mml:mi>T</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>g</mml:mi></mml:mrow></mml:msub><mml:mo>*</mml:mo><mml:mi>T</mml:mi><mml:mi>c</mml:mi><mml:mo>*</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>g</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>&#x003bb;</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:mi>c</mml:mi><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>g</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives><label>(Eq 9)</label></disp-formula>
<disp-formula id="pone.0203030.e014"><alternatives><graphic xlink:href="pone.0203030.e014.jpg" id="pone.0203030.e014g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M14"><mml:mrow><mml:mo>&#x02022;</mml:mo><mml:mspace width="0.50em"/><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>g</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>&#x003b3;</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>g</mml:mi></mml:mrow></mml:msub><mml:mo>*</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>g</mml:mi></mml:mrow></mml:msub><mml:mo>*</mml:mo><mml:msub><mml:mi>M</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>g</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003bb;</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>g</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>&#x02013;</mml:mo><mml:msub><mml:mi>&#x003b4;</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>g</mml:mi></mml:mrow></mml:msub><mml:mo>*</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>g</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>&#x003bc;</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>g</mml:mi><mml:mi>C</mml:mi><mml:mi>k</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>*</mml:mo><mml:mfrac><mml:mrow><mml:mi>I</mml:mi><mml:mi>L</mml:mi><mml:mn>10</mml:mn><mml:mo>*</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>g</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>g</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mn>11</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives><label>(Eq 10)</label></disp-formula>
<disp-formula id="pone.0203030.e015"><alternatives><graphic xlink:href="pone.0203030.e015.jpg" id="pone.0203030.e015g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M15"><mml:mrow><mml:mo>&#x02022;</mml:mo><mml:mspace width="0.50em"/><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>I</mml:mi><mml:mi>L</mml:mi><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mrow><mml:mi>M</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>*</mml:mo><mml:msub><mml:mi>M</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>&#x02013;</mml:mo><mml:msub><mml:mi>&#x003b4;</mml:mi><mml:mrow><mml:mi>C</mml:mi><mml:mi>k</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>*</mml:mo><mml:mi>I</mml:mi><mml:mi>L</mml:mi><mml:mn>10</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>g</mml:mi></mml:mrow></mml:msub><mml:mo>*</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>g</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:mi>h</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>*</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mi>H</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives><label>(Eq 11)</label></disp-formula>
<disp-formula id="pone.0203030.e016"><alternatives><graphic xlink:href="pone.0203030.e016.jpg" id="pone.0203030.e016g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M16"><mml:mrow><mml:mo>&#x02022;</mml:mo><mml:mspace width="0.50em"/><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>I</mml:mi><mml:mi>F</mml:mi><mml:mi>N</mml:mi><mml:mi>&#x003b3;</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:mi>h</mml:mi><mml:mn>1</mml:mn><mml:mi>C</mml:mi><mml:mi>K</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>*</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mi>H</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:mi>c</mml:mi></mml:mrow></mml:msub><mml:mo>*</mml:mo><mml:mi>T</mml:mi><mml:mi>c</mml:mi><mml:mo>&#x02013;</mml:mo><mml:msub><mml:mi>&#x003b4;</mml:mi><mml:mrow><mml:mi>C</mml:mi><mml:mi>k</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>*</mml:mo><mml:mi>I</mml:mi><mml:mi>F</mml:mi><mml:mi>N</mml:mi><mml:mi>&#x003b3;</mml:mi></mml:mrow></mml:math></alternatives><label>(Eq 12)</label></disp-formula>
<disp-formula id="pone.0203030.e017"><alternatives><graphic xlink:href="pone.0203030.e017.jpg" id="pone.0203030.e017g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M17"><mml:mrow><mml:mo>&#x02022;</mml:mo><mml:mspace width="0.50em"/><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>I</mml:mi><mml:mi>L</mml:mi><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:mi>h</mml:mi><mml:mn>1</mml:mn><mml:mi>C</mml:mi><mml:mi>K</mml:mi><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>*</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mi>H</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mi>&#x003b4;</mml:mi><mml:mrow><mml:mi>C</mml:mi><mml:mi>k</mml:mi><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>*</mml:mo><mml:mi>I</mml:mi><mml:mi>L</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:math></alternatives><label>(Eq 13)</label></disp-formula></p></sec><sec id="sec024"><title>7.3. Control and therapeutic strategies</title><list list-type="alpha-lower"><list-item><p><bold>Radiotherapy (R) -</bold> With the aim to reduce the tumor cell proliferation, control variables were introduced in our model. Here, the control variable u1 signifies the probability of cell death due to Radiotherapy (<xref ref-type="disp-formula" rid="pone.0203030.e018">Eq 14</xref>),
<disp-formula id="pone.0203030.e018"><alternatives><graphic xlink:href="pone.0203030.e018.jpg" id="pone.0203030.e018g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M18"><mml:mrow><mml:mi mathvariant="normal">u</mml:mi><mml:mn>1</mml:mn><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mi>&#x02011;</mml:mi><mml:mi mathvariant="normal">exp</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>&#x02011;</mml:mi><mml:msub><mml:mrow><mml:mi mathvariant="normal">&#x003b1;</mml:mi><mml:mi mathvariant="normal">d</mml:mi></mml:mrow><mml:mi mathvariant="normal">R</mml:mi></mml:msub><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">&#x003b2;</mml:mi><mml:mi mathvariant="normal">d</mml:mi></mml:mrow><mml:mi mathvariant="normal">R</mml:mi></mml:msub><mml:msup><mml:mrow/><mml:mn>2</mml:mn></mml:msup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives><label>(Eq 14)</label></disp-formula>
where &#x003b1; and &#x003b2; are the parameters governing the radio-sensitivity of the cells, and d<sub>R</sub> is the dose of radiotherapy applied, measured in Grey (Gy) units [<xref rid="pone.0203030.ref057" ref-type="bibr">57</xref>]. The value of &#x003b1; and &#x003b2; depends on the oxygenation state of the cell [<xref rid="pone.0203030.ref058" ref-type="bibr">58</xref>]. In our model it has been considered that Radiotherapy affects only the Cancer (C) and the Cancer Resistant (Cr) populations of the tumor. It has no effect on the stem cells owing to their slow growth rate.</p></list-item><list-item><p><bold>Chemotherapy (C)</bold> - The control variable u2, signifying chemotherapy has an effect on the drug-sensitive stem (S) and cancer (C) cells of the tumor (<xref ref-type="disp-formula" rid="pone.0203030.e019">Eq 15</xref>). u2_S and u2_C are defined as the probabilities of cell death, due to chemotherapy, of Stem cells and Cancer cells respectively (<xref ref-type="disp-formula" rid="pone.0203030.e019">Eq 15</xref> and <xref ref-type="disp-formula" rid="pone.0203030.e020">Eq 16</xref>).
<disp-formula id="pone.0203030.e019"><alternatives><graphic xlink:href="pone.0203030.e019.jpg" id="pone.0203030.e019g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M19"><mml:mrow><mml:mi mathvariant="normal">u</mml:mi><mml:mn>2</mml:mn><mml:mo>_</mml:mo><mml:mi mathvariant="normal">S</mml:mi><mml:mo>=</mml:mo><mml:msub><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">C</mml:mi></mml:msub><mml:mi mathvariant="normal">*</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mi>&#x02011;</mml:mi><mml:mi mathvariant="normal">exp</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>&#x02011;</mml:mi><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mi mathvariant="normal">C</mml:mi></mml:msub><mml:mi mathvariant="normal">*</mml:mi><mml:msub><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">C</mml:mi></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>&#x02011;</mml:mi><mml:msub><mml:mi mathvariant="normal">k</mml:mi><mml:mi mathvariant="normal">S</mml:mi></mml:msub></mml:mrow></mml:math></alternatives><label>(Eq 15)</label></disp-formula>
<disp-formula id="pone.0203030.e020"><alternatives><graphic xlink:href="pone.0203030.e020.jpg" id="pone.0203030.e020g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M20"><mml:mrow><mml:mi mathvariant="normal">u</mml:mi><mml:mn>2</mml:mn><mml:mo>_</mml:mo><mml:mi mathvariant="normal">C</mml:mi><mml:mo>=</mml:mo><mml:msub><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">C</mml:mi></mml:msub><mml:mi mathvariant="normal">*</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mi>&#x02011;</mml:mi><mml:mi mathvariant="normal">exp</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>&#x02011;</mml:mi><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mi mathvariant="normal">C</mml:mi></mml:msub><mml:mi mathvariant="normal">*</mml:mi><mml:msub><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">C</mml:mi></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives><label>(Eq 16)</label></disp-formula></p><p>Here, f<sub>C</sub> denotes the frequency of chemotherapy per day, M is defined as the efficiency of the chemotherapeutic drug in m<sup>2</sup>mg<sup>-1</sup> denoting the area of the tumor affected per mg of the drug and d<sub>C</sub> is the concentration of the drug in mg m<sup>-2</sup>. The efficacy of the chemotherapy of the stem cells depends on the factor k<sub>S</sub> that represent the inhibitory effect of IL-4 on the stem cells that reduces the efficacy of the drugs. Sequestration of IL-4 makes the stem cells sensitive to chemotherapy [<xref rid="pone.0203030.ref044" ref-type="bibr">44</xref>, <xref rid="pone.0203030.ref059" ref-type="bibr">59</xref>].</p></list-item><list-item><p><bold>Immunotherapy (I) -</bold> The parameter set was systematically screened to identify key parameters governing the negative feedback of the immune cells on the Tumor population. Then, the immunotherapy was introduced in our model as perturbations to the system in order to overcome the immunosuppressive effect of the tumor cells and to restore a healthy T<sub>H1</sub> /T<sub>H2</sub> balance.
<disp-formula id="pone.0203030.e021"><alternatives><graphic xlink:href="pone.0203030.e021.jpg" id="pone.0203030.e021g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M21"><mml:mrow><mml:mi mathvariant="normal">u</mml:mi><mml:mn>3</mml:mn><mml:mo>_</mml:mo><mml:mi mathvariant="normal">Tc</mml:mi><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">d</mml:mi></mml:mrow><mml:mi mathvariant="normal">I</mml:mi></mml:msub><mml:mi mathvariant="normal">*</mml:mi><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mi mathvariant="normal">TC</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives><label>(Eq 17)</label></disp-formula>
<disp-formula id="pone.0203030.e022"><alternatives><graphic xlink:href="pone.0203030.e022.jpg" id="pone.0203030.e022g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M22"><mml:mrow><mml:mi mathvariant="normal">u</mml:mi><mml:mn>3</mml:mn><mml:mo>_</mml:mo><mml:mi mathvariant="normal">TH</mml:mi><mml:mn>1</mml:mn><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">d</mml:mi></mml:mrow><mml:mi mathvariant="normal">I</mml:mi></mml:msub><mml:mi mathvariant="normal">*</mml:mi><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mi mathvariant="normal">TH</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives><label>(Eq 18)</label></disp-formula></p><p><xref ref-type="disp-formula" rid="pone.0203030.e021">Eq 17</xref> and <xref ref-type="disp-formula" rid="pone.0203030.e022">Eq 18</xref> depicts the control variables for providing immune-boost to the T<sub>C</sub> and T<sub>H1</sub> cells, respectively. d<sub>I</sub> signifies the dose of immunostimulant, measured in mg day<sup>-1</sup> that must be given to the system, while M<sub>TC</sub> and M<sub>TH1</sub> are the measures of the sensitivity of the T<sub>C</sub> and T<sub>H1</sub> cells, respectively.</p></list-item></list></sec><sec id="sec025"><title>7.4. Designing treatment protocols</title><p>The protocols are designed using various combination of the above mentioned treatment strategies, viz. <italic>Radiotherapy</italic>, <italic>Chemotherapy</italic> and <italic>Immunotherapy</italic>. The dosage, time duration and number of cycles for each therapy are varied to determine the optimal combination that gives us maximum fold changes in the tumor reduction. The general form of the protocols can be described as follows:
<disp-formula id="pone.0203030.e023"><alternatives><graphic xlink:href="pone.0203030.e023.jpg" id="pone.0203030.e023g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M23"><mml:msub><mml:mrow><mml:mi>D</mml:mi><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mn>200</mml:mn></mml:mrow></mml:msub><mml:mo>&#x02192;</mml:mo><mml:msub><mml:mrow><mml:msubsup><mml:mrow><mml:mo>(</mml:mo><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>t</mml:mi><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>R</mml:mi></mml:mrow><mml:mo>/</mml:mo><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:mrow></mml:mrow></mml:msubsup><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:mo>&#x02192;</mml:mo><mml:msub><mml:mrow><mml:mi>F</mml:mi><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mi>t</mml:mi><mml:mi>F</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msub><mml:mo>&#x02192;</mml:mo><mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mrow><mml:mi>C</mml:mi><mml:mi>h</mml:mi></mml:mrow><mml:mrow><mml:mi>t</mml:mi><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:msub><mml:mo>&#x02192;</mml:mo><mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mrow><mml:mi>I</mml:mi></mml:mrow><mml:mrow><mml:mi>t</mml:mi><mml:mi>I</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>I</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mi>I</mml:mi></mml:mrow></mml:msub></mml:math></alternatives></disp-formula></p><p>Here, <italic>Ch</italic> denotes Chemotherapy, <italic>R</italic> denotes Radiotherapy and <italic>FT</italic> signifies a treatment-free period or relaxation time. The model was run till 200 days before the start of any therapeutic interventions. This has been considered as the standard detection time (<italic>DT</italic>) for a full grown tumor. Here the subscripts (t<sub>R</sub>, t<sub>C</sub> and t<sub>I</sub>) denotes the time duration for which the treatment was given, and the superscripts (d<sub>R</sub>, d<sub>C</sub> and d<sub>I</sub>) represent the dosage. The subscript outside the bracket (n<sub>R</sub>, n<sub>C</sub> and t<sub>I</sub>) denotes the number of cycles for which that treatment was repeated.</p><sec id="sec026"><title>7.4.1. Protocol 1</title><p>This Protocol is an adaptation of the standard treatment protocol used for applying chemo and radiotherapy (adapted from British Columbia Cancer Agency Protocol GIGAJCPRT - <ext-link ext-link-type="uri" xlink:href="http://www.bccancer.bc.ca/">http://www.bccancer.bc.ca/</ext-link>). It was applied to our model to observe the fold changes in the tumor cell population. The protocol can be summarized as follows:
<disp-formula id="pone.0203030.e024"><alternatives><graphic xlink:href="pone.0203030.e024.jpg" id="pone.0203030.e024g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M24"><mml:msub><mml:mrow><mml:mi>D</mml:mi><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mn>200</mml:mn></mml:mrow></mml:msub><mml:mo>&#x02192;</mml:mo><mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mrow><mml:mi>C</mml:mi><mml:mi>h</mml:mi></mml:mrow><mml:mrow><mml:mn>14</mml:mn></mml:mrow><mml:mrow><mml:mn>800</mml:mn></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mn>6</mml:mn></mml:mrow></mml:msub><mml:mo>&#x02192;</mml:mo><mml:msubsup><mml:mrow><mml:mo>(</mml:mo><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mn>40</mml:mn></mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mn>60</mml:mn></mml:mrow><mml:mo>/</mml:mo><mml:mrow><mml:mn>28</mml:mn></mml:mrow></mml:mrow></mml:mrow></mml:msubsup><mml:mo>)</mml:mo><mml:mo>&#x02192;</mml:mo><mml:msub><mml:mrow><mml:mi>F</mml:mi><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mn>15</mml:mn></mml:mrow></mml:msub><mml:mo>&#x02192;</mml:mo><mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mrow><mml:mi>C</mml:mi><mml:mi>h</mml:mi></mml:mrow><mml:mrow><mml:mn>14</mml:mn></mml:mrow><mml:mrow><mml:mn>800</mml:mn></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mn>6</mml:mn></mml:mrow></mml:msub></mml:math></alternatives></disp-formula></p></sec><sec id="sec027"><title>7.4.2. Protocol 2</title><p>This Protocol was designed as a combinatorial treatment protocol of Chemotherapy, Radiotherapy and Immunotherapy to enhance the treatment efficacy. Based on Protocol 1, this Protocol is an improvisation where Immunotherapy has been included that boosts both the T<sub>H1</sub> and Tc simultaneously. In order to design this combinatorial treatment protocol, the dose of Radio, Chemo and Immunotherapy were varied over wide ranges in order to create 1000 treatment combinations. The treatment efficacy of each combination was plotted in a 4-dimensional scatter plot, measured in terms of fold change and T<sub>H1</sub>/T<sub>H2</sub> ratio (<xref ref-type="supplementary-material" rid="pone.0203030.s002">S1 Fig</xref>). The Protocol 2 can be summarized as follows:
<disp-formula id="pone.0203030.e025"><alternatives><graphic xlink:href="pone.0203030.e025.jpg" id="pone.0203030.e025g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M25"><mml:msub><mml:mrow><mml:mi>D</mml:mi><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mn>200</mml:mn></mml:mrow></mml:msub><mml:mo>&#x02192;</mml:mo><mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mrow><mml:mi>C</mml:mi><mml:mi>h</mml:mi></mml:mrow><mml:mrow><mml:mn>14</mml:mn></mml:mrow><mml:mrow><mml:mn>800</mml:mn></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mn>6</mml:mn></mml:mrow></mml:msub><mml:mo>&#x02192;</mml:mo><mml:msubsup><mml:mrow><mml:mo>(</mml:mo><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mn>40</mml:mn></mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mn>60</mml:mn></mml:mrow><mml:mo>/</mml:mo><mml:mrow><mml:mn>28</mml:mn></mml:mrow></mml:mrow></mml:mrow></mml:msubsup><mml:mo>)</mml:mo><mml:mo>&#x02192;</mml:mo><mml:msub><mml:mrow><mml:mi>F</mml:mi><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mn>15</mml:mn></mml:mrow></mml:msub><mml:mo>&#x02192;</mml:mo><mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mrow><mml:mi>C</mml:mi><mml:mi>h</mml:mi></mml:mrow><mml:mrow><mml:mn>14</mml:mn></mml:mrow><mml:mrow><mml:mn>800</mml:mn></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mn>6</mml:mn></mml:mrow></mml:msub><mml:mo>&#x02192;</mml:mo><mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mrow><mml:mi>I</mml:mi></mml:mrow><mml:mrow><mml:mn>20</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mn>10</mml:mn></mml:mrow></mml:msub></mml:math></alternatives></disp-formula></p></sec><sec id="sec028"><title>7.4.3. Measuring treatment efficacy</title><p>The efficacy of a treatment protocol is measured by the reduction in the size of the tumor and the overall recovery from the immune-suppression induced by the tumor, to ensure minimal chances of tumor relapse. Hence we have defined two parameters that can be used as an indicator of Cancer prognosis:</p><list list-type="alpha-lower"><list-item><p><bold>Fold Change</bold> &#x02013; The treatment efficacy was estimated by measuring the fold change of the tumor mass at the end of the treatment period as compared to the tumor mass measured at the time of detection.</p></list-item><list-item><p><bold>T</bold><sub><bold>H1</bold></sub><bold>/T</bold><sub><bold>H2</bold></sub>
<bold>ratio</bold> - In order to ensure maximum treatment efficacy and minimize chances of Cancer relapse, the T<sub>H1</sub>/T<sub>H2</sub> ratio was used as an indicator for disease prognosis. A minimum threshold of T<sub>H1</sub>/T<sub>H2</sub> &#x02265; 5 was chosen to optimize treatment protocol.</p></list-item></list></sec></sec><sec id="sec029"><title>7.5. Positivity and boundedness</title><p>This system of equations (Section 1.2, Eqs <xref ref-type="disp-formula" rid="pone.0203030.e005">1</xref>&#x02013;<xref ref-type="disp-formula" rid="pone.0203030.e017">13</xref>) can be analyzed with the initial conditions (<xref ref-type="supplementary-material" rid="pone.0203030.s001">S1 Text</xref>) defined in the thirteen dimensional variable space
<disp-formula id="pone.0203030.e026"><alternatives><graphic xlink:href="pone.0203030.e026.jpg" id="pone.0203030.e026g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M26"><mml:msubsup><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow><mml:mrow><mml:mn>13</mml:mn></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mo>[</mml:mo><mml:mo>(</mml:mo><mml:mrow><mml:mi>S</mml:mi><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mi>C</mml:mi><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mi>M</mml:mi><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>M</mml:mi><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mi>H</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mi>H</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mi>T</mml:mi><mml:mi>c</mml:mi><mml:mo>,</mml:mo><mml:mi>T</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>g</mml:mi><mml:mo>,</mml:mo><mml:mi>I</mml:mi><mml:mi>L</mml:mi><mml:mn>10</mml:mn><mml:mo>,</mml:mo><mml:mi>I</mml:mi><mml:mi>F</mml:mi><mml:mi>N</mml:mi><mml:mi>&#x003b3;</mml:mi><mml:mo>,</mml:mo><mml:mi>I</mml:mi><mml:mi>L</mml:mi><mml:mn>2</mml:mn></mml:mrow><mml:mo>)</mml:mo><mml:mo>&#x02208;</mml:mo><mml:msup><mml:mrow><mml:mi mathvariant="fraktur">R</mml:mi></mml:mrow><mml:mrow><mml:mn>13</mml:mn></mml:mrow></mml:msup><mml:mo>|</mml:mo><mml:mo>(</mml:mo><mml:mrow><mml:mi>S</mml:mi><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mi>C</mml:mi><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mi>M</mml:mi><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>M</mml:mi><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mi>H</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mi>H</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mi>T</mml:mi><mml:mi>c</mml:mi><mml:mo>,</mml:mo><mml:mi>T</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>g</mml:mi><mml:mo>,</mml:mo><mml:mi>I</mml:mi><mml:mi>L</mml:mi><mml:mn>10</mml:mn><mml:mo>,</mml:mo><mml:mi>I</mml:mi><mml:mi>F</mml:mi><mml:mi>N</mml:mi><mml:mi>&#x003b3;</mml:mi><mml:mo>,</mml:mo><mml:mi>I</mml:mi><mml:mi>L</mml:mi><mml:mn>2</mml:mn></mml:mrow><mml:mo>)</mml:mo><mml:mo>&#x02265;</mml:mo><mml:mn>0</mml:mn><mml:mo>]</mml:mo></mml:math></alternatives></disp-formula></p><p>It can be proven, that all solutions of the system in <inline-formula id="pone.0203030.e027"><alternatives><graphic xlink:href="pone.0203030.e027.jpg" id="pone.0203030.e027g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M27"><mml:msubsup><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>+</mml:mo></mml:mrow><mml:mrow><mml:mn>13</mml:mn></mml:mrow></mml:msubsup></mml:math></alternatives></inline-formula> remain in <inline-formula id="pone.0203030.e028"><alternatives><graphic xlink:href="pone.0203030.e028.jpg" id="pone.0203030.e028g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M28"><mml:msubsup><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>+</mml:mo></mml:mrow><mml:mrow><mml:mn>13</mml:mn></mml:mrow></mml:msubsup></mml:math></alternatives></inline-formula>. Hence, <inline-formula id="pone.0203030.e029"><alternatives><graphic xlink:href="pone.0203030.e029.jpg" id="pone.0203030.e029g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M29"><mml:msubsup><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>+</mml:mo></mml:mrow><mml:mrow><mml:mn>13</mml:mn></mml:mrow></mml:msubsup></mml:math></alternatives></inline-formula> is positively invariant, and it is sufficient to consider solutions only in <inline-formula id="pone.0203030.e030"><alternatives><graphic xlink:href="pone.0203030.e030.jpg" id="pone.0203030.e030g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M30"><mml:msubsup><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>+</mml:mo></mml:mrow><mml:mrow><mml:mn>13</mml:mn></mml:mrow></mml:msubsup></mml:math></alternatives></inline-formula>. In this region, the usual existence, uniqueness and continuation results hold for the system. From our numerical simulations also, we have observed the existence of positive solutions. The solution set we get for the set of ODEs represents the effective cell population and protein concentrations of the species considered in the model at different time points during the tumor development. The fixed point attained by all the variables of the model is a part of this positive solution space.</p><p>Also, we observe that the right-hand side of Eqs <xref ref-type="disp-formula" rid="pone.0203030.e005">1</xref>&#x02013;<xref ref-type="disp-formula" rid="pone.0203030.e017">13</xref> (Section 1.2) are smooth functions of the variables (S, S<sub>R</sub>, C, C<sub>R</sub>, M1, M2, T<sub>H1</sub>, T<sub>H2</sub>, Tc, Treg, IL10, IFN&#x003b3;, IL2). Also, since all the parameters are non-negative, local existence and uniqueness properties hold in <inline-formula id="pone.0203030.e031"><alternatives><graphic xlink:href="pone.0203030.e031.jpg" id="pone.0203030.e031g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M31"><mml:msubsup><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow><mml:mrow><mml:mn>13</mml:mn></mml:mrow></mml:msubsup></mml:math></alternatives></inline-formula>, and if the following necessary conditions are satisfied,</p><list list-type="order"><list-item><p>S<sub>0</sub> &#x0003e; 0</p></list-item><list-item><p>p<sub>1</sub>+p<sub>2</sub> &#x0003c; 1</p></list-item><list-item><p>m<sub>S</sub> &#x0003c; 1</p></list-item><list-item><p>m<sub>C</sub> &#x0003c; 1</p></list-item><list-item><p>&#x003b3;<sub>S</sub>(1-p<sub>2</sub>) &#x0003e; &#x003b4;<sub>S</sub></p></list-item></list><p specific-use="continuation">then, we can state the following proposition.</p><p><bold>Proposition 1:</bold> All the solutions of Eqs <xref ref-type="disp-formula" rid="pone.0203030.e005">1</xref>&#x02013;<xref ref-type="disp-formula" rid="pone.0203030.e017">13</xref> (Section 1.2) which initiate in <inline-formula id="pone.0203030.e032"><alternatives><graphic xlink:href="pone.0203030.e032.jpg" id="pone.0203030.e032g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M32"><mml:msubsup><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow><mml:mrow><mml:mn>13</mml:mn></mml:mrow></mml:msubsup></mml:math></alternatives></inline-formula> are uniformly bounded.</p><p><bold>Proof:</bold> The proof of Proposition 1 is obvious as all the variables satisfy the condition of positive invariance for all the solutions of Eqs <xref ref-type="disp-formula" rid="pone.0203030.e005">1</xref>&#x02013;<xref ref-type="disp-formula" rid="pone.0203030.e017">13</xref> (Section 1.2) which initiate in <inline-formula id="pone.0203030.e033"><alternatives><graphic xlink:href="pone.0203030.e033.jpg" id="pone.0203030.e033g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M33"><mml:msubsup><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow><mml:mrow><mml:mn>13</mml:mn></mml:mrow></mml:msubsup></mml:math></alternatives></inline-formula>, the assumptions and necessary conditions (stated in Section 1.3) [<xref rid="pone.0203030.ref060" ref-type="bibr">60</xref>].</p></sec><sec id="sec030"><title>7.6. Sensitivity analysis</title><p>The sensitivity analysis of the model was performed by the extended Fourier Amplitude Sensitivity Test eFAST technique using a MATLAB based toolbox [<xref rid="pone.0203030.ref061" ref-type="bibr">61</xref>]. The sensitivity analysis was carried out using the whole set of parameters [k = 71]. 100 samples were chosen per search curve and resampling of the search curves was carried out 5 times [N<sub>S</sub> = 100, N<sub>R</sub> = 5]. Hence, the total number of model simulations N = (k+1)*Ns*N<sub>R</sub> = 36000. The Sensitivity Indices (Si) of the parameters (p&#x0003c;0.05) for the variables governing the growth of the tumor sub-populations, <italic>viz</italic>. S, S<sub>R</sub>, C and C<sub>R</sub> were estimated at different stages of the tumor development (<xref ref-type="fig" rid="pone.0203030.g006">Fig 6A&#x02013;6D</xref>). Here it may be observed that at different time points that Si values of the parameters change, signifying the importance of the parameters in the different stages of the tumor development. The knowledge from this sensitivity analysis was used to determine the parameters that have a maximum effect on the tumor development.</p><fig id="pone.0203030.g006" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0203030.g006</object-id><label>Fig 6</label><caption><p><bold>Sensitivity analysis and parameter estimation:</bold> (a-d) Sensitivity Analysis plots for S, S<sub>R</sub>, C and C<sub>R</sub> respectively. The x-axis represents the parameters with p&#x0003c;0.05; (e) Trace Plot showing the best fitting parameter values as estimated by the MCMC algorithm; (f) Predictive plot of cancer proliferation using the estimated parameter values. The red circles represent the cancer cell proliferation values as obtained from Cell Counting experiments using Gastric Cancer cell line [<xref rid="pone.0203030.ref029" ref-type="bibr">29</xref>].</p></caption><graphic xlink:href="pone.0203030.g006"/></fig></sec><sec id="sec031"><title>7.7. Parameter estimation from Cancer cell line data</title><p>The model comprises of a total of 71 parameters. The values of 21 parameters of the model were curated from the existing literature. The unknown parameters were estimated (few were assumed within the biological feasible ranges) using the MATLAB based toolbox that employs the MCMC-DRAM algorithm for parameter estimation [<xref rid="pone.0203030.ref062" ref-type="bibr">62</xref>]. The time course experiment cytometric data for cancer cell proliferation obtained for 7 days in for Gastric cancer cell line (SGC7901) that was fitted for approximating the cancer cell behavior during the growth phase (<xref ref-type="fig" rid="pone.0203030.g006">Fig 6F</xref>) [<xref rid="pone.0203030.ref029" ref-type="bibr">29</xref>]. Parameters that were sensitive for the growth of the Cancer (C sub-population) cells were varied in biologically feasible ranges. The prior distribution was assumed to be normal and the MCMC simulation was carried out for 5 lakh iterations to ensure the convergence of the chain (<xref ref-type="fig" rid="pone.0203030.g006">Fig 6E</xref>). The estimated parameter values for the model have been listed in <xref ref-type="supplementary-material" rid="pone.0203030.s001">S1 Text</xref>.</p></sec><sec id="sec032"><title>7.8. Experimental data for model calibration</title><p>Apart from the parameters estimated using the MCMC method, the remaining unknown parameters governing the steady state behavior of the system were manually adjusted within the biologically feasible ranges for the calibration of the model so as to ensure that the simulation results corroborated with the various experimental observations. These parameter values (labelled as &#x02019;Expected&#x02019;) used for the numerical simulation of the model have been enlisted in <xref ref-type="supplementary-material" rid="pone.0203030.s001">S1 Text</xref>. The experimental data used for this purpose were extracted from the available literature. For the validation of the growth kinetics of the resistant Cancer cells, time-course data of resistant cell lines were obtained from Breast cancer cell line MCF-7/TAX-resistant to Paclitaxel [<xref rid="pone.0203030.ref031" ref-type="bibr">31</xref>], Hepatocellular Carcinoma cell line SK-Hep1/CDDP3-resistant to Cisplatin [<xref rid="pone.0203030.ref032" ref-type="bibr">32</xref>], Colon Cancer cell lines SW-620-L-OHP and LoVo-L-OHP-resistant to Oxaliplatin [<xref rid="pone.0203030.ref033" ref-type="bibr">33</xref>]. The cytometric data obtained for the validation of the immune cell ratios were mostly obtained from Gastric Cancer, Ovarian Cancer and Osteosarcoma studies [<xref rid="pone.0203030.ref034" ref-type="bibr">34</xref>&#x02013;<xref rid="pone.0203030.ref039" ref-type="bibr">39</xref>]. The data for the validation of cytokine expression were obtained from cases of Gastric and Breast Cancer studies [<xref rid="pone.0203030.ref040" ref-type="bibr">40</xref>&#x02013;<xref rid="pone.0203030.ref042" ref-type="bibr">42</xref>]. These data used came from heterogeneous sources as none of the previously performed experiments were found to report the values of all cytometric data in a single experiment. Moreover, the use of data from the different Cancer studies ensures that the model is generic and mimics the average behavior observed in most Cancer studies. The use of data from both <italic>in vitro</italic> studies as well as data obtained from Cancer patients ensures the reliability of the model for its use in designing therapeutic control. In order to make the model specific for a single type of Cancer, one needs to simply obtain the cytometric data from a single experimental source and adjust the parameters accordingly.</p></sec><sec id="sec033"><title>7.9. Interior equilibria</title><p>To ensure positivity and existence of the interior equilibrium solutions, 36000 random parameter sets were generated (as mentioned in Section 7.6) within the biologically feasible ranges. Thereafter the model is simulated up to 800 days for each set of parameter. It was observed that each model simulation led to the positive interior equilibrium solution. Hence, we can state and prove the following Proposition.</p><p><bold>Proposition 2:</bold> Positive interior equilibria exists for the set of equations Eqs <xref ref-type="disp-formula" rid="pone.0203030.e005">1</xref>&#x02013;<xref ref-type="disp-formula" rid="pone.0203030.e017">13</xref> (Section 1.2).</p><p>Proof: The interior equilibrium points are the steady-state solutions of the Eqs <xref ref-type="disp-formula" rid="pone.0203030.e005">1</xref>&#x02013;<xref ref-type="disp-formula" rid="pone.0203030.e017">13</xref> (Section 1.2) under the necessary conditions (Section 1.3) in the biologically feasible ranges of parameter values and initial conditions <xref ref-type="supplementary-material" rid="pone.0203030.s001">S1 Text</xref>.</p></sec><sec id="sec034"><title>7.10. Model initialization and numerical simulation</title><p>The tumor mass is formed by the sub-populations S, S<sub>R</sub>, C, C<sub>R</sub>. In our model, the S cell sub-population has been initialized to 1, while all the other tumor cell sub-populations have been considered as 0. The initial values of the remaining variables have been initialized based on cytometric data and cytokine expression values of healthy individuals, curated from the literature. The details have been provided in the <xref ref-type="supplementary-material" rid="pone.0203030.s001">S1 Text</xref>. The model was simulated numerically using the variable-step, variable order solver, ode15s, in MATLAB&#x000ae; 2017a platform.</p></sec></sec><sec sec-type="supplementary-material" id="sec035"><title>Supporting information</title><supplementary-material content-type="local-data" id="pone.0203030.s001"><label>S1 Text</label><caption><title>Model parameters.</title><p>The Supplementary Text contains the description of the parameters and state variables used for the model simulations.</p><p>(DOCX)</p></caption><media xlink:href="pone.0203030.s001.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0203030.s002"><label>S1 Fig</label><caption><title>Treatment conditions under varying dose of Radiotherapy, Chemotherapy and Immunotherapy.</title><p>The scatter plot depicts (a) the fold change of tumor population and (b) T<sub>H1</sub>/T<sub>H2</sub> ratio under 1000 treatment combinations.</p><p>(TIF)</p></caption><media xlink:href="pone.0203030.s002.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>Piyali Ganguli acknowledges the Council of Scientific &#x00026; Industrial Research (CSIR) for the Junior Research Fellowship.</p></ack><ref-list><title>References</title><ref id="pone.0203030.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Tan</surname><given-names>BT</given-names></name>, <name><surname>Park</surname><given-names>CY</given-names></name>, <name><surname>Ailles</surname><given-names>LE</given-names></name>, <name><surname>Weissman</surname><given-names>IL</given-names></name>. <article-title>The cancer stem cell hypothesis: a work in progress</article-title>. <source>Laboratory Investigation</source>. <year>2006</year>;<volume>86</volume>(<issue>12</issue>):<fpage>1203</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1038/labinvest.3700488</pub-id>
<pub-id pub-id-type="pmid">17075578</pub-id></mixed-citation></ref><ref id="pone.0203030.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Fidler</surname><given-names>IJ</given-names></name>. <article-title>The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited</article-title>. <source>Nature reviews Cancer</source>. <year>2003</year>;<volume>3</volume>(<issue>6</issue>):<fpage>453</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1038/nrc1098</pub-id> .<pub-id pub-id-type="pmid">12778135</pub-id></mixed-citation></ref><ref id="pone.0203030.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Tomasetti</surname><given-names>C</given-names></name>, <name><surname>Levy</surname><given-names>D</given-names></name>. <article-title>Role of symmetric and asymmetric division of stem cells in developing drug resistance</article-title>. <source>Proceedings of the National Academy of Sciences of the United States of America</source>. <year>2010</year>;<volume>107</volume>(<issue>39</issue>):<fpage>16766</fpage>&#x02013;<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1007726107</pub-id> ; PubMed Central PMCID: PMC2947914.<pub-id pub-id-type="pmid">20826440</pub-id></mixed-citation></ref><ref id="pone.0203030.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Zahreddine</surname><given-names>H</given-names></name>, <name><surname>Borden</surname><given-names>KLB</given-names></name>. <article-title>Mechanisms and insights into drug resistance in cancer</article-title>. <source>Frontiers in Pharmacology</source>. <year>2013</year>;<volume>4</volume>:<fpage>28</fpage>
<pub-id pub-id-type="doi">10.3389/fphar.2013.00028</pub-id> PMC3596793. <pub-id pub-id-type="pmid">23504227</pub-id></mixed-citation></ref><ref id="pone.0203030.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Chew</surname><given-names>V</given-names></name>, <name><surname>Toh</surname><given-names>HC</given-names></name>, <name><surname>Abastado</surname><given-names>JP</given-names></name>. <article-title>Immune microenvironment in tumor progression: characteristics and challenges for therapy</article-title>. <source>Journal of oncology</source>. <year>2012</year>;<volume>2012</volume>:<fpage>608406</fpage>
<pub-id pub-id-type="doi">10.1155/2012/608406</pub-id> ; PubMed Central PMCID: PMC3423944.<pub-id pub-id-type="pmid">22927846</pub-id></mixed-citation></ref><ref id="pone.0203030.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Papaccio</surname><given-names>F</given-names></name>, <name><surname>Paino</surname><given-names>F</given-names></name>, <name><surname>Regad</surname><given-names>T</given-names></name>, <name><surname>Papaccio</surname><given-names>G</given-names></name>, <name><surname>Desiderio</surname><given-names>V</given-names></name>, <name><surname>Tirino</surname><given-names>V</given-names></name>. <article-title>Concise review: cancer cells, cancer stem cells, and mesenchymal stem cells: influence in cancer development</article-title>. <source>Stem cells translational medicine</source>. <year>2017</year>;<volume>6</volume>(<issue>12</issue>):<fpage>2115</fpage>&#x02013;<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1002/sctm.17-0138</pub-id>
<pub-id pub-id-type="pmid">29072369</pub-id></mixed-citation></ref><ref id="pone.0203030.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Bellone</surname><given-names>G</given-names></name>, <name><surname>Turletti</surname><given-names>A</given-names></name>, <name><surname>Artusio</surname><given-names>E</given-names></name>, <name><surname>Mareschi</surname><given-names>K</given-names></name>, <name><surname>Carbone</surname><given-names>A</given-names></name>, <name><surname>Tibaudi</surname><given-names>D</given-names></name>, <etal>et al</etal>
<article-title>Tumor-associated transforming growth factor-&#x003b2; and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients</article-title>. <source>The American journal of pathology</source>. <year>1999</year>;<volume>155</volume>(<issue>2</issue>):<fpage>537</fpage>&#x02013;<lpage>47</lpage>. <pub-id pub-id-type="pmid">10433946</pub-id></mixed-citation></ref><ref id="pone.0203030.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Ostuni</surname><given-names>R</given-names></name>, <name><surname>Kratochvill</surname><given-names>F</given-names></name>, <name><surname>Murray</surname><given-names>PJ</given-names></name>, <name><surname>Natoli</surname><given-names>G</given-names></name>. <article-title>Macrophages and cancer: from mechanisms to therapeutic implications</article-title>. <source>Trends in immunology</source>. <year>2015</year>;<volume>36</volume>(<issue>4</issue>):<fpage>229</fpage>&#x02013;<lpage>39</lpage>. <pub-id pub-id-type="doi">10.1016/j.it.2015.02.004</pub-id>
<pub-id pub-id-type="pmid">25770924</pub-id></mixed-citation></ref><ref id="pone.0203030.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Hirohashi</surname><given-names>Y</given-names></name>, <name><surname>Torigoe</surname><given-names>T</given-names></name>, <name><surname>Tsukahara</surname><given-names>T</given-names></name>, <name><surname>Kanaseki</surname><given-names>T</given-names></name>, <name><surname>Kochin</surname><given-names>V</given-names></name>, <name><surname>Sato</surname><given-names>N</given-names></name>. <article-title>Immune responses to human cancer stem-like cells/cancer-initiating cells</article-title>. <source>Cancer Science</source>. <year>2016</year>;<volume>107</volume>(<issue>1</issue>):<fpage>12</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1111/cas.12830</pub-id>
<pub-id pub-id-type="pmid">26440127</pub-id></mixed-citation></ref><ref id="pone.0203030.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Bell</surname><given-names>E</given-names></name>, <name><surname>Taylor</surname><given-names>MA</given-names></name>. <article-title>Functional roles for exosomal microRNAs in the tumour microenvironment</article-title>. <source>Computational and structural biotechnology journal</source>. <year>2017</year>;<volume>15</volume>:<fpage>8</fpage>&#x02013;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1016/j.csbj.2016.10.005</pub-id>
<pub-id pub-id-type="pmid">27872688</pub-id></mixed-citation></ref><ref id="pone.0203030.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Neviani</surname><given-names>P</given-names></name>, <name><surname>Fabbri</surname><given-names>M</given-names></name>. <article-title>Exosomic microRNAs in the tumor microenvironment</article-title>. <source>Frontiers in medicine</source>. <year>2015</year>;<volume>2</volume>:<fpage>47</fpage>
<pub-id pub-id-type="doi">10.3389/fmed.2015.00047</pub-id>
<pub-id pub-id-type="pmid">26258125</pub-id></mixed-citation></ref><ref id="pone.0203030.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Ohm</surname><given-names>JE</given-names></name>, <name><surname>Gabrilovich</surname><given-names>DI</given-names></name>, <name><surname>Sempowski</surname><given-names>GD</given-names></name>, <name><surname>Kisseleva</surname><given-names>E</given-names></name>, <name><surname>Parman</surname><given-names>KS</given-names></name>, <name><surname>Nadaf</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression</article-title>. <source>Blood</source>. <year>2003</year>;<volume>101</volume>(<issue>12</issue>):<fpage>4878</fpage>&#x02013;<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2002-07-1956</pub-id>
<pub-id pub-id-type="pmid">12586633</pub-id></mixed-citation></ref><ref id="pone.0203030.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Ziogas</surname><given-names>AC</given-names></name>, <name><surname>Gavalas</surname><given-names>NG</given-names></name>, <name><surname>Tsiatas</surname><given-names>M</given-names></name>, <name><surname>Tsitsilonis</surname><given-names>O</given-names></name>, <name><surname>Politi</surname><given-names>E</given-names></name>, <name><surname>Terpos</surname><given-names>E</given-names></name>, <etal>et al</etal>
<article-title>VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor Type 2</article-title>. <source>International journal of cancer</source>. <year>2012</year>;<volume>130</volume>(<issue>4</issue>):<fpage>857</fpage>&#x02013;<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1002/ijc.26094</pub-id>
<pub-id pub-id-type="pmid">21445972</pub-id></mixed-citation></ref><ref id="pone.0203030.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Paino</surname><given-names>F</given-names></name>, <name><surname>La Noce</surname><given-names>M</given-names></name>, <name><surname>Di Nucci</surname><given-names>D</given-names></name>, <name><surname>Nicoletti</surname><given-names>GF</given-names></name>, <name><surname>Salzillo</surname><given-names>R</given-names></name>, <name><surname>De Rosa</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Human adipose stem cell differentiation is highly affected by cancer cells both in vitro and in vivo: implication for autologous fat grafting</article-title>. <source>Cell death &#x00026; disease</source>. <year>2017</year>;<volume>8</volume>(<issue>1</issue>):<fpage>e2568</fpage>.<pub-id pub-id-type="pmid">28102844</pub-id></mixed-citation></ref><ref id="pone.0203030.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Stellavato</surname><given-names>A</given-names></name>, <name><surname>La Noce</surname><given-names>M</given-names></name>, <name><surname>Corsuto</surname><given-names>L</given-names></name>, <name><surname>Pirozzi</surname><given-names>AVA</given-names></name>, <name><surname>De Rosa</surname><given-names>M</given-names></name>, <name><surname>Papaccio</surname><given-names>G</given-names></name>, <etal>et al</etal>
<article-title>Hybrid complexes of high and low molecular weight hyaluronans highly enhance HASCs differentiation: implication for facial bioremodelling</article-title>. <source>Cellular Physiology and Biochemistry</source>. <year>2017</year>;<volume>44</volume>(<issue>3</issue>):<fpage>1078</fpage>&#x02013;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1159/000485414</pub-id>
<pub-id pub-id-type="pmid">29179206</pub-id></mixed-citation></ref><ref id="pone.0203030.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Whiteside</surname><given-names>TL</given-names></name>. <article-title>The tumor microenvironment and its role in promoting tumor growth</article-title>. <source>Oncogene</source>. <year>2008</year>;<volume>27</volume>(<issue>45</issue>):<fpage>5904</fpage>&#x02013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1038/onc.2008.271</pub-id> ; PubMed Central PMCID: PMC3689267.<pub-id pub-id-type="pmid">18836471</pub-id></mixed-citation></ref><ref id="pone.0203030.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Gammaitoni</surname><given-names>L</given-names></name>, <name><surname>Leuci</surname><given-names>V</given-names></name>, <name><surname>Mesiano</surname><given-names>G</given-names></name>, <name><surname>Giraudo</surname><given-names>L</given-names></name>, <name><surname>Todorovic</surname><given-names>M</given-names></name>, <name><surname>Carnevale-Schianca</surname><given-names>F</given-names></name>, <etal>et al</etal>
<article-title>Immunotherapy of cancer stem cells in solid tumors: initial findings and future prospective</article-title>. <source>Expert opinion on biological therapy</source>. <year>2014</year>;<volume>14</volume>(<issue>9</issue>):<fpage>1259</fpage>&#x02013;<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1517/14712598.2014.918099</pub-id>
<pub-id pub-id-type="pmid">24835841</pub-id></mixed-citation></ref><ref id="pone.0203030.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Liao</surname><given-names>T</given-names></name>, <name><surname>Kaufmann</surname><given-names>AM</given-names></name>, <name><surname>Qian</surname><given-names>X</given-names></name>, <name><surname>Sangvatanakul</surname><given-names>V</given-names></name>, <name><surname>Chen</surname><given-names>C</given-names></name>, <name><surname>Kube</surname><given-names>T</given-names></name>, <etal>et al</etal>
<article-title>Susceptibility to cytotoxic T cell lysis of cancer stem cells derived from cervical and head and neck tumor cell lines</article-title>. <source>Journal of cancer research and clinical oncology</source>. <year>2013</year>;<volume>139</volume>(<issue>1</issue>):<fpage>159</fpage>&#x02013;<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1007/s00432-012-1311-2</pub-id>
<pub-id pub-id-type="pmid">23001491</pub-id></mixed-citation></ref><ref id="pone.0203030.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Chen</surname><given-names>H-C</given-names></name>, <name><surname>Joalland</surname><given-names>N</given-names></name>, <name><surname>Bridgeman</surname><given-names>JS</given-names></name>, <name><surname>Alchami</surname><given-names>FS</given-names></name>, <name><surname>Jarry</surname><given-names>U</given-names></name>, <name><surname>Khan</surname><given-names>MWA</given-names></name>, <etal>et al</etal>
<article-title>Synergistic targeting of breast cancer stem-like cells by human &#x003b3;&#x003b4; T cells and CD8(+) T cells</article-title>. <source>Immunology and Cell Biology</source>. <year>2017</year>;<volume>95</volume>(<issue>7</issue>):<fpage>620</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1038/icb.2017.21</pub-id> PMC5550559. <pub-id pub-id-type="pmid">28356569</pub-id></mixed-citation></ref><ref id="pone.0203030.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Guo</surname><given-names>Y</given-names></name>, <name><surname>Feng</surname><given-names>K</given-names></name>, <name><surname>Wang</surname><given-names>Y</given-names></name>, <name><surname>Han</surname><given-names>W</given-names></name>. <article-title>Targeting cancer stem cells by using chimeric antigen receptor-modified T cells: a potential and curable approach for cancer treatment</article-title>. <source>Protein &#x00026; cell</source>. <year>2017</year>:<fpage>1</fpage>&#x02013;<lpage>11</lpage>.<pub-id pub-id-type="pmid">27094622</pub-id></mixed-citation></ref><ref id="pone.0203030.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Agliano</surname><given-names>A</given-names></name>, <name><surname>Calvo</surname><given-names>A</given-names></name>, <name><surname>Box</surname><given-names>C</given-names></name>. <article-title>The challenge of targeting cancer stem cells to halt metastasis</article-title>. <source>Seminars in Cancer Biology</source>. <year>2017</year>;<volume>44</volume>:<fpage>25</fpage>&#x02013;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1016/j.semcancer.2017.03.003</pub-id>
<pub-id pub-id-type="pmid">28323021</pub-id></mixed-citation></ref><ref id="pone.0203030.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>McHale</surname><given-names>PT</given-names></name>, <name><surname>Lander</surname><given-names>AD</given-names></name>. <article-title>The Protective Role of Symmetric Stem Cell Division on the Accumulation of Heritable Damage</article-title>. <source>PLOS Computational Biology</source>. <year>2014</year>;<volume>10</volume>(<issue>8</issue>):<fpage>e1003802</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pcbi.1003802</pub-id>
<pub-id pub-id-type="pmid">25121484</pub-id></mixed-citation></ref><ref id="pone.0203030.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Kirschner</surname><given-names>D</given-names></name>, <name><surname>Panetta</surname><given-names>JC</given-names></name>. <article-title>Modeling immunotherapy of the tumor&#x02013;immune interaction</article-title>. <source>Journal of mathematical biology</source>. <year>1998</year>;<volume>37</volume>(<issue>3</issue>):<fpage>235</fpage>&#x02013;<lpage>52</lpage>. <pub-id pub-id-type="pmid">9785481</pub-id></mixed-citation></ref><ref id="pone.0203030.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>de Pillis</surname><given-names>LG</given-names></name>, <name><surname>Radunskaya</surname><given-names>AE</given-names></name>, <name><surname>Wiseman</surname><given-names>CL</given-names></name>. <article-title>A Validated Mathematical Model of Cell-Mediated Immune Response to Tumor Growth</article-title>. <source>Cancer Research</source>. <year>2005</year>;<volume>65</volume>(<issue>17</issue>):<fpage>7950</fpage>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-0564</pub-id>
<pub-id pub-id-type="pmid">16140967</pub-id></mixed-citation></ref><ref id="pone.0203030.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>De Boer</surname><given-names>RJ</given-names></name>, <name><surname>Hogeweg</surname><given-names>P</given-names></name>, <name><surname>Dullens</surname><given-names>HF</given-names></name>, <name><surname>De Weger</surname><given-names>RA</given-names></name>, <name><surname>Den Otter</surname><given-names>W</given-names></name>. <article-title>Macrophage T lymphocyte interactions in the anti-tumor immune response: a mathematical model</article-title>. <source>The Journal of Immunology</source>. <year>1985</year>;<volume>134</volume>(<issue>4</issue>):<fpage>2748</fpage>
<pub-id pub-id-type="pmid">3156189</pub-id></mixed-citation></ref><ref id="pone.0203030.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Robertson-Tessi</surname><given-names>M</given-names></name>, <name><surname>El-Kareh</surname><given-names>A</given-names></name>, <name><surname>Goriely</surname><given-names>A</given-names></name>. <article-title>A mathematical model of tumor&#x02013;immune interactions</article-title>. <source>Journal of Theoretical Biology</source>. <year>2012</year>;<volume>294</volume>:<fpage>56</fpage>&#x02013;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1016/j.jtbi.2011.10.027</pub-id>
<pub-id pub-id-type="pmid">22051568</pub-id></mixed-citation></ref><ref id="pone.0203030.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>De Pillis</surname><given-names>LG</given-names></name>, <name><surname>Radunskaya</surname><given-names>A</given-names></name>. <article-title>A mathematical tumor model with immune resistance and drug therapy: an optimal control approach</article-title>. <source>Journal of Theoretical Medicine</source>. <year>2001</year>;<volume>3</volume>(<issue>2</issue>):<fpage>79</fpage>&#x02013;<lpage>100</lpage>. <pub-id pub-id-type="doi">10.1080/10273660108833067</pub-id></mixed-citation></ref><ref id="pone.0203030.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Krishnapriya</surname><given-names>P</given-names></name>, <name><surname>Pitchaimani</surname><given-names>M</given-names></name>. <article-title>Optimal control of mixed immunotherapy and chemotherapy of tumours with discrete delay</article-title>. <source>International Journal of Dynamics and Control</source>. <year>2015</year>
<pub-id pub-id-type="doi">10.1007/s40435-015-0221-y</pub-id></mixed-citation></ref><ref id="pone.0203030.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Ning</surname><given-names>X</given-names></name>, <name><surname>Sun</surname><given-names>S</given-names></name>, <name><surname>Hong</surname><given-names>L</given-names></name>, <name><surname>Liang</surname><given-names>J</given-names></name>, <name><surname>Liu</surname><given-names>L</given-names></name>, <name><surname>Han</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Calcyclin-binding protein inhibits proliferation, tumorigenicity, and invasion of gastric cancer</article-title>. <source>Molecular cancer research: MCR</source>. <year>2007</year>;<volume>5</volume>(<issue>12</issue>):<fpage>1254</fpage>&#x02013;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1158/1541-7786.MCR-06-0426</pub-id> .<pub-id pub-id-type="pmid">18171983</pub-id></mixed-citation></ref><ref id="pone.0203030.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Pan</surname><given-names>Q</given-names></name>, <name><surname>Li</surname><given-names>Q</given-names></name>, <name><surname>Liu</surname><given-names>S</given-names></name>, <name><surname>Ning</surname><given-names>N</given-names></name>, <name><surname>Zhang</surname><given-names>X</given-names></name>, <name><surname>Xu</surname><given-names>Y</given-names></name>, <etal>et al</etal>
<article-title>Concise Review: Targeting Cancer Stem Cells Using Immunologic Approaches</article-title>. <source>Stem Cells</source>. <year>2015</year>;<volume>33</volume>(<issue>7</issue>):<fpage>2085</fpage>&#x02013;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1002/stem.2039</pub-id>
<pub-id pub-id-type="pmid">25873269</pub-id></mixed-citation></ref><ref id="pone.0203030.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Chen</surname><given-names>S-Y</given-names></name>, <name><surname>Hu</surname><given-names>S-S</given-names></name>, <name><surname>Dong</surname><given-names>Q</given-names></name>, <name><surname>Cai</surname><given-names>J-X</given-names></name>, <name><surname>Zhang</surname><given-names>W-P</given-names></name>, <name><surname>Sun</surname><given-names>J-Y</given-names></name>, <etal>et al</etal>
<article-title>Establishment of Paclitaxel-resistant Breast Cancer Cell Line and Nude Mice Models, and Underlying Multidrug Resistance Mechanisms in Vitro and in Vivo</article-title>. <source>Asian Pacific Journal of Cancer Prevention</source>. <year>2013</year>;<volume>14</volume>(<issue>10</issue>):<fpage>6135</fpage>&#x02013;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.7314/apjcp.2013.14.10.6135</pub-id>
<pub-id pub-id-type="pmid">24289639</pub-id></mixed-citation></ref><ref id="pone.0203030.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Ling</surname><given-names>X</given-names></name>, <name><surname>Wen</surname><given-names>L</given-names></name>, <name><surname>Zhou</surname><given-names>Y</given-names></name>. <article-title>Role of mitochondrial translocation of telomerase in hepatocellular carcinoma cells with multidrug resistance</article-title>. <source>International journal of medical sciences</source>. <year>2012</year>;<volume>9</volume>(<issue>7</issue>):<fpage>545</fpage>&#x02013;<lpage>54</lpage>. <pub-id pub-id-type="doi">10.7150/ijms.4648</pub-id> ; PubMed Central PMCID: PMC3444975.<pub-id pub-id-type="pmid">22991493</pub-id></mixed-citation></ref><ref id="pone.0203030.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>Z</given-names></name>, <name><surname>Qiu</surname><given-names>M</given-names></name>, <name><surname>Tang</surname><given-names>QL</given-names></name>, <name><surname>Liu</surname><given-names>M</given-names></name>, <name><surname>Lang</surname><given-names>N</given-names></name>, <name><surname>Bi</surname><given-names>F</given-names></name>. <article-title>Establishment and biological characteristics of oxaliplatin-resistant human colon cancer cell lines</article-title>. <source>Chinese journal of cancer</source>. <year>2010</year>;<volume>29</volume>(<issue>7</issue>):<fpage>661</fpage>&#x02013;<lpage>7</lpage>. .<pub-id pub-id-type="pmid">20591218</pub-id></mixed-citation></ref><ref id="pone.0203030.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>Markowska</surname><given-names>J</given-names></name>, <name><surname>Lacki</surname><given-names>J</given-names></name>, <name><surname>Jaroszewski</surname><given-names>J</given-names></name>, <name><surname>Wiktorowicz</surname><given-names>K</given-names></name>. <article-title>The usefulness of CD4/CD8 ratio evaluation in monitoring of ovarian cancer patients</article-title>. <source>European journal of gynaecological oncology</source>. <year>1995</year>;<volume>16</volume>(<issue>1</issue>):<fpage>54</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="pmid">7744118</pub-id></mixed-citation></ref><ref id="pone.0203030.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>Biller</surname><given-names>BJ</given-names></name>, <name><surname>Guth</surname><given-names>A</given-names></name>, <name><surname>Burton</surname><given-names>JH</given-names></name>, <name><surname>Dow</surname><given-names>SW</given-names></name>. <article-title>Decreased Ratio of CD8+ T Cells to Regulatory T Cells Associated with Decreased Survival in Dogs with Osteosarcoma</article-title>. <source>Journal of veterinary internal medicine / American College of Veterinary Internal Medicine</source>. <year>2010</year>;<volume>24</volume>(<issue>5</issue>):<fpage>1118</fpage>&#x02013;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1111/j.1939-1676.2010.0557.x</pub-id> PMC3557512. <pub-id pub-id-type="pmid">20666983</pub-id></mixed-citation></ref><ref id="pone.0203030.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>K</given-names></name>, <name><surname>Yang</surname><given-names>K</given-names></name>, <name><surname>Wu</surname><given-names>B</given-names></name>, <name><surname>Chen</surname><given-names>H</given-names></name>, <name><surname>Chen</surname><given-names>X</given-names></name>, <name><surname>Chen</surname><given-names>X</given-names></name>, <etal>et al</etal>
<article-title>Tumor-Infiltrating Immune Cells Are Associated With Prognosis of Gastric Cancer</article-title>. <source>Medicine</source>. <year>2015</year>;<volume>94</volume>(<issue>39</issue>):<fpage>e1631</fpage>
<pub-id pub-id-type="doi">10.1097/MD.0000000000001631</pub-id> PMC4616881. <pub-id pub-id-type="pmid">26426650</pub-id></mixed-citation></ref><ref id="pone.0203030.ref037"><label>37</label><mixed-citation publication-type="journal"><name><surname>Balachandran</surname><given-names>VP</given-names></name>, <name><surname>Cavnar</surname><given-names>MJ</given-names></name>, <name><surname>Zeng</surname><given-names>S</given-names></name>, <name><surname>Bamboat</surname><given-names>ZM</given-names></name>, <name><surname>Ocuin</surname><given-names>LM</given-names></name>, <name><surname>Obaid</surname><given-names>H</given-names></name>, <etal>et al</etal>
<article-title>Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido</article-title>. <source>Nature medicine</source>. <year>2011</year>;<volume>17</volume>(<issue>9</issue>):<fpage>1094</fpage>&#x02013;<lpage>100</lpage>. <pub-id pub-id-type="doi">10.1038/nm.2438</pub-id> ; PubMed Central PMCID: PMC3278279.<pub-id pub-id-type="pmid">21873989</pub-id></mixed-citation></ref><ref id="pone.0203030.ref038"><label>38</label><mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>M</given-names></name>, <name><surname>He</surname><given-names>Y</given-names></name>, <name><surname>Sun</surname><given-names>X</given-names></name>, <name><surname>Li</surname><given-names>Q</given-names></name>, <name><surname>Wang</surname><given-names>W</given-names></name>, <name><surname>Zhao</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>A high M1/M2 ratio of tumor-associated macrophages is associated with extended survival in ovarian cancer patients</article-title>. <source>Journal of Ovarian Research</source>. <year>2014</year>;<volume>7</volume>:<fpage>19</fpage>&#x02013;. <pub-id pub-id-type="doi">10.1186/1757-2215-7-19</pub-id> PMC3939626. <pub-id pub-id-type="pmid">24507759</pub-id></mixed-citation></ref><ref id="pone.0203030.ref039"><label>39</label><mixed-citation publication-type="journal"><name><surname>Ubukata</surname><given-names>H</given-names></name>, <name><surname>Motohashi</surname><given-names>G</given-names></name>, <name><surname>Tabuchi</surname><given-names>T</given-names></name>, <name><surname>Nagata</surname><given-names>H</given-names></name>, <name><surname>Konishi</surname><given-names>S</given-names></name>, <name><surname>Tabuchi</surname><given-names>T</given-names></name>. <article-title>Evaluations of interferon-gamma/interleukin-4 ratio and neutrophil/lymphocyte ratio as prognostic indicators in gastric cancer patients</article-title>. <source>Journal of surgical oncology</source>. <year>2010</year>;<volume>102</volume>(<issue>7</issue>):<fpage>742</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1002/jso.21725</pub-id> .<pub-id pub-id-type="pmid">20872813</pub-id></mixed-citation></ref><ref id="pone.0203030.ref040"><label>40</label><mixed-citation publication-type="journal"><name><surname>Hong</surname><given-names>CC</given-names></name>, <name><surname>Yao</surname><given-names>S</given-names></name>, <name><surname>McCann</surname><given-names>SE</given-names></name>, <name><surname>Dolnick</surname><given-names>RY</given-names></name>, <name><surname>Wallace</surname><given-names>PK</given-names></name>, <name><surname>Gong</surname><given-names>Z</given-names></name>, <etal>et al</etal>
<article-title>Pretreatment levels of circulating Th1 and Th2 cytokines, and their ratios, are associated with ER-negative and triple negative breast cancers</article-title>. <source>Breast cancer research and treatment</source>. <year>2013</year>;<volume>139</volume>(<issue>2</issue>):<fpage>477</fpage>&#x02013;<lpage>88</lpage>. <pub-id pub-id-type="doi">10.1007/s10549-013-2549-3</pub-id> ; PubMed Central PMCID: PMC3912696.<pub-id pub-id-type="pmid">23624818</pub-id></mixed-citation></ref><ref id="pone.0203030.ref041"><label>41</label><mixed-citation publication-type="journal"><name><surname>Szaflarska</surname><given-names>A</given-names></name>, <name><surname>Szczepanik</surname><given-names>A</given-names></name>, <name><surname>Siedlar</surname><given-names>M</given-names></name>, <name><surname>Czupryna</surname><given-names>A</given-names></name>, <name><surname>SIER&#x0017b;&#x00118;GA</surname><given-names>M</given-names></name>, <name><surname>Popiela</surname><given-names>T</given-names></name>, <etal>et al</etal>
<article-title>Preoperative plasma level of IL-10 but not of proinflammatory cytokines is an independent prognostic factor in patients with gastric cancer</article-title>. <source>Anticancer research</source>. <year>2009</year>;<volume>29</volume>(<issue>12</issue>):<fpage>5005</fpage>&#x02013;<lpage>12</lpage>. <pub-id pub-id-type="pmid">20044609</pub-id></mixed-citation></ref><ref id="pone.0203030.ref042"><label>42</label><mixed-citation publication-type="journal"><name><surname>Gupta</surname><given-names>M</given-names></name>, <name><surname>Han</surname><given-names>JJ</given-names></name>, <name><surname>Stenson</surname><given-names>M</given-names></name>, <name><surname>Maurer</surname><given-names>M</given-names></name>, <name><surname>Wellik</surname><given-names>L</given-names></name>, <name><surname>Hu</surname><given-names>G</given-names></name>, <etal>et al</etal>
<article-title>Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation</article-title>. <source>Blood</source>. <year>2012</year>;<volume>119</volume>(<issue>12</issue>):<fpage>2844</fpage>&#x02013;<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2011-10-388538</pub-id> PMC3327462. <pub-id pub-id-type="pmid">22323454</pub-id></mixed-citation></ref><ref id="pone.0203030.ref043"><label>43</label><mixed-citation publication-type="journal"><name><surname>Yuan</surname><given-names>A</given-names></name>, <name><surname>Hsiao</surname><given-names>Y-J</given-names></name>, <name><surname>Chen</surname><given-names>H-Y</given-names></name>, <name><surname>Chen</surname><given-names>H-W</given-names></name>, <name><surname>Ho</surname><given-names>C-C</given-names></name>, <name><surname>Chen</surname><given-names>Y-Y</given-names></name>, <etal>et al</etal>
<article-title>Opposite Effects of M1 and M2 Macrophage Subtypes on Lung Cancer Progression</article-title>. <source>Scientific Reports</source>. <year>2015</year>;<volume>5</volume>:<fpage>14273</fpage>
<pub-id pub-id-type="doi">10.1038/srep14273</pub-id>
<ext-link ext-link-type="uri" xlink:href="https://www.nature.com/articles/srep14273#supplementary-information">https://www.nature.com/articles/srep14273#supplementary-information</ext-link>. <pub-id pub-id-type="pmid">26399191</pub-id></mixed-citation></ref><ref id="pone.0203030.ref044"><label>44</label><mixed-citation publication-type="journal"><name><surname>Rich</surname><given-names>JN</given-names></name>, <name><surname>Bao</surname><given-names>S</given-names></name>. <article-title>Chemotherapy and cancer stem cells</article-title>. <source>Cell stem cell</source>. <year>2007</year>;<volume>1</volume>(<issue>4</issue>):<fpage>353</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1016/j.stem.2007.09.011</pub-id> .<pub-id pub-id-type="pmid">18371369</pub-id></mixed-citation></ref><ref id="pone.0203030.ref045"><label>45</label><mixed-citation publication-type="journal"><name><surname>Kim</surname><given-names>Y</given-names></name>, <name><surname>Joo</surname><given-names>KM</given-names></name>, <name><surname>Jin</surname><given-names>J</given-names></name>, <name><surname>Nam</surname><given-names>D-H</given-names></name>. <article-title>Cancer Stem Cells and Their Mechanism of Chemo-Radiation Resistance</article-title>. <source>International Journal of Stem Cells</source>. <year>2009</year>;<volume>2</volume>(<issue>2</issue>):<fpage>109</fpage>&#x02013;<lpage>14</lpage>. PMC4021765. <pub-id pub-id-type="pmid">24855529</pub-id></mixed-citation></ref><ref id="pone.0203030.ref046"><label>46</label><mixed-citation publication-type="journal"><name><surname>Hazem</surname><given-names>G</given-names></name>, <name><surname>Monther</surname><given-names>A-A</given-names></name>. <article-title>Do Cancer Stem Cells have an Immunomodulatory Role Different from the Bulk of Tumor Cells?</article-title>
<source>Journal of Carcinogenesis &#x00026; Mutagenesis</source>. <year>2013</year>;0(0):-. <pub-id pub-id-type="doi">10.4172/2157-2518.S14-003</pub-id></mixed-citation></ref><ref id="pone.0203030.ref047"><label>47</label><mixed-citation publication-type="journal"><name><surname>Jiang</surname><given-names>X</given-names></name>. <article-title>Macrophage-produced IL-10 limits the chemotherapy efficacy in breast cancer</article-title>. <source>Journal of Zhejiang University Science B</source>. <year>2015</year>;<volume>16</volume>(<issue>1</issue>):<fpage>44</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1631/jzus.B1400352</pub-id> PMC4288943. <pub-id pub-id-type="pmid">25559954</pub-id></mixed-citation></ref><ref id="pone.0203030.ref048"><label>48</label><mixed-citation publication-type="journal"><name><surname>Mele</surname><given-names>L</given-names></name>, <name><surname>Paino</surname><given-names>F</given-names></name>, <name><surname>Papaccio</surname><given-names>F</given-names></name>, <name><surname>Regad</surname><given-names>T</given-names></name>, <name><surname>Boocock</surname><given-names>D</given-names></name>, <name><surname>Stiuso</surname><given-names>P</given-names></name>, <etal>et al</etal>
<article-title>A new inhibitor of glucose-6-phosphate dehydrogenase blocks pentose phosphate pathway and suppresses malignant proliferation and metastasis in vivo</article-title>. <source>Cell death &#x00026; disease</source>. <year>2018</year>;<volume>9</volume>(<issue>5</issue>):<fpage>572</fpage>.<pub-id pub-id-type="pmid">29760380</pub-id></mixed-citation></ref><ref id="pone.0203030.ref049"><label>49</label><mixed-citation publication-type="journal"><name><surname>Demicheli</surname><given-names>R</given-names></name>, <name><surname>Pratesi</surname><given-names>G</given-names></name>, <name><surname>Foroni</surname><given-names>R</given-names></name>. <article-title>The exponential-Gompertzian tumor growth model: data from six tumor cell lines in vitro and in vivo. Estimate of the transition point from exponential to Gompertzian growth and potential clinical implications</article-title>. <source>Tumori</source>. <year>1991</year>;<volume>77</volume>(<issue>3</issue>):<fpage>189</fpage>&#x02013;<lpage>95</lpage>. <pub-id pub-id-type="pmid">1862544</pub-id></mixed-citation></ref><ref id="pone.0203030.ref050"><label>50</label><mixed-citation publication-type="journal"><name><surname>Mills</surname><given-names>CD</given-names></name>, <name><surname>Ley</surname><given-names>K</given-names></name>. <article-title>M1 and M2 Macrophages: The Chicken and the Egg of Immunity</article-title>. <source>Journal of Innate Immunity</source>. <year>2014</year>;<volume>6</volume>(<issue>6</issue>):<fpage>716</fpage>&#x02013;<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1159/000364945</pub-id>
<pub-id pub-id-type="pmid">25138714</pub-id></mixed-citation></ref><ref id="pone.0203030.ref051"><label>51</label><mixed-citation publication-type="journal"><name><surname>Sun</surname><given-names>W</given-names></name>, <name><surname>Wei</surname><given-names>F-Q</given-names></name>, <name><surname>Li</surname><given-names>W-J</given-names></name>, <name><surname>Wei</surname><given-names>J-W</given-names></name>, <name><surname>Zhong</surname><given-names>H</given-names></name>, <name><surname>Wen</surname><given-names>Y-H</given-names></name>, <etal>et al</etal>
<article-title>A positive-feedback loop between tumour infiltrating activated Treg cells and type 2-skewed macrophages is essential for progression of laryngeal squamous cell carcinoma</article-title>. <source>British Journal Of Cancer</source>. <year>2017</year>;<volume>117</volume>:<fpage>1631</fpage>
<pub-id pub-id-type="doi">10.1038/bjc.2017.329</pub-id>
<ext-link ext-link-type="uri" xlink:href="https://www.nature.com/articles/bjc2017329#supplementary-information">https://www.nature.com/articles/bjc2017329#supplementary-information</ext-link>. <pub-id pub-id-type="pmid">28949956</pub-id></mixed-citation></ref><ref id="pone.0203030.ref052"><label>52</label><mixed-citation publication-type="journal"><name><surname>Kwiatkowska-Borowczyk</surname><given-names>EP</given-names></name>, <name><surname>G&#x00105;bka-Buszek</surname><given-names>A</given-names></name>, <name><surname>Jankowski</surname><given-names>J</given-names></name>, <name><surname>Mackiewicz</surname><given-names>A</given-names></name>. <article-title>Immunotargeting of cancer stem cells</article-title>. <source>Contemporary Oncology</source>. <year>2015</year>;<volume>19</volume>(<issue>1A</issue>):<fpage>A52</fpage>&#x02013;<lpage>A9</lpage>. <pub-id pub-id-type="doi">10.5114/wo.2014.47129</pub-id> PMC4322523. <pub-id pub-id-type="pmid">25691822</pub-id></mixed-citation></ref><ref id="pone.0203030.ref053"><label>53</label><mixed-citation publication-type="journal"><name><surname>Beavis</surname><given-names>PA</given-names></name>, <name><surname>Petley</surname><given-names>EV</given-names></name>, <name><surname>Darcy</surname><given-names>PK</given-names></name>. <article-title>A novel combination strategy for effectively targeting cancer stem-like cells</article-title>. <source>Immunology And Cell Biology</source>. <year>2017</year>;<volume>95</volume>:<fpage>573</fpage>
<pub-id pub-id-type="doi">10.1038/icb.2017.39</pub-id>
<pub-id pub-id-type="pmid">28529324</pub-id></mixed-citation></ref><ref id="pone.0203030.ref054"><label>54</label><mixed-citation publication-type="journal"><name><surname>Chen</surname><given-names>M-L</given-names></name>, <name><surname>Pittet</surname><given-names>MJ</given-names></name>, <name><surname>Gorelik</surname><given-names>L</given-names></name>, <name><surname>Flavell</surname><given-names>RA</given-names></name>, <name><surname>Weissleder</surname><given-names>R</given-names></name>, <name><surname>von Boehmer</surname><given-names>H</given-names></name>, <etal>et al</etal>
<article-title>Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-&#x003b2; signals &#x00026;lt;em&#x00026;gt;in vivo&#x00026;lt;/em&#x00026;gt</article-title>. <source>Proceedings of the National Academy of Sciences of the United States of America</source>. <year>2005</year>;<volume>102</volume>(<issue>2</issue>):<fpage>419</fpage>
<pub-id pub-id-type="doi">10.1073/pnas.0408197102</pub-id>
<pub-id pub-id-type="pmid">15623559</pub-id></mixed-citation></ref><ref id="pone.0203030.ref055"><label>55</label><mixed-citation publication-type="journal"><name><surname>Huang</surname><given-names>H</given-names></name>, <name><surname>Hao</surname><given-names>S</given-names></name>, <name><surname>Li</surname><given-names>F</given-names></name>, <name><surname>Ye</surname><given-names>Z</given-names></name>, <name><surname>Yang</surname><given-names>J</given-names></name>, <name><surname>Xiang</surname><given-names>J</given-names></name>. <article-title>CD4(+) Th1 cells promote CD8(+) Tc1 cell survival, memory response, tumor localization and therapy by targeted delivery of interleukin 2 via acquired pMHC I complexes</article-title>. <source>Immunology</source>. <year>2007</year>;<volume>120</volume>(<issue>2</issue>):<fpage>148</fpage>&#x02013;<lpage>59</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2567.2006.02452.x</pub-id> PMC2265849. <pub-id pub-id-type="pmid">17274112</pub-id></mixed-citation></ref><ref id="pone.0203030.ref056"><label>56</label><mixed-citation publication-type="journal"><name><surname>de Pillis</surname><given-names>LG</given-names></name>. <source>Mathematical Modeling of the Regulatory T Cell E ffects on Renal Cell Carcinoma Treatment</source>. <year>2013</year>.</mixed-citation></ref><ref id="pone.0203030.ref057"><label>57</label><mixed-citation publication-type="journal"><name><surname>Powathil</surname><given-names>GG</given-names></name>, <name><surname>Adamson</surname><given-names>DJ</given-names></name>, <name><surname>Chaplain</surname><given-names>MA</given-names></name>. <article-title>Towards predicting the response of a solid tumour to chemotherapy and radiotherapy treatments: clinical insights from a computational model</article-title>. <source>PLoS Comput Biol</source>. <year>2013</year>;<volume>9</volume>(<issue>7</issue>):<fpage>e1003120</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pcbi.1003120</pub-id> ; PubMed Central PMCID: PMC3708873.<pub-id pub-id-type="pmid">23874170</pub-id></mixed-citation></ref><ref id="pone.0203030.ref058"><label>58</label><mixed-citation publication-type="journal"><name><surname>Powathil</surname><given-names>G</given-names></name>, <name><surname>Kohandel</surname><given-names>M</given-names></name>, <name><surname>Milosevic</surname><given-names>M</given-names></name>, <name><surname>Sivaloganathan</surname><given-names>S</given-names></name>. <article-title>Modeling the spatial distribution of chronic tumor hypoxia: implications for experimental and clinical studies</article-title>. <source>Computational and mathematical methods in medicine</source>. <year>2012</year>;<volume>2012</volume>:<fpage>410602</fpage>
<pub-id pub-id-type="doi">10.1155/2012/410602</pub-id> ; PubMed Central PMCID: PMC3287099.<pub-id pub-id-type="pmid">22400049</pub-id></mixed-citation></ref><ref id="pone.0203030.ref059"><label>59</label><mixed-citation publication-type="journal"><name><surname>Abdullah</surname><given-names>LN</given-names></name>, <name><surname>Chow</surname><given-names>EK</given-names></name>. <article-title>Mechanisms of chemoresistance in cancer stem cells</article-title>. <source>Clinical and translational medicine</source>. <year>2013</year>;<volume>2</volume>(<issue>1</issue>):<fpage>3</fpage>
<pub-id pub-id-type="doi">10.1186/2001-1326-2-3</pub-id> ; PubMed Central PMCID: PMC3565873.<pub-id pub-id-type="pmid">23369605</pub-id></mixed-citation></ref><ref id="pone.0203030.ref060"><label>60</label><mixed-citation publication-type="book"><name><surname>Birkhoff</surname><given-names>G</given-names></name>, <name><surname>Rota</surname><given-names>G</given-names></name>. <source>Ordinary differential equations</source>, <publisher-name>John Wiley&#x00026; Sons. Inc</publisher-name>; <year>1978</year>.</mixed-citation></ref><ref id="pone.0203030.ref061"><label>61</label><mixed-citation publication-type="journal"><name><surname>Marino</surname><given-names>S</given-names></name>, <name><surname>Hogue</surname><given-names>IB</given-names></name>, <name><surname>Ray</surname><given-names>CJ</given-names></name>, <name><surname>Kirschner</surname><given-names>DE</given-names></name>. <article-title>A methodology for performing global uncertainty and sensitivity analysis in systems biology</article-title>. <source>J Theor Biol</source>. <year>2008</year>;<volume>254</volume>(<issue>1</issue>):<fpage>178</fpage>&#x02013;<lpage>96</lpage>. <pub-id pub-id-type="doi">10.1016/j.jtbi.2008.04.011</pub-id> ; PubMed Central PMCID: PMC2570191.<pub-id pub-id-type="pmid">18572196</pub-id></mixed-citation></ref><ref id="pone.0203030.ref062"><label>62</label><mixed-citation publication-type="journal"><name><surname>Haario</surname><given-names>H</given-names></name>, <name><surname>Laine</surname><given-names>M</given-names></name>, <name><surname>Mira</surname><given-names>A</given-names></name>, <name><surname>Saksman</surname><given-names>E</given-names></name>. <article-title>DRAM: efficient adaptive MCMC</article-title>. <source>Statistics and Computing</source>. <year>2006</year>;<volume>16</volume>(<issue>4</issue>):<fpage>339</fpage>&#x02013;<lpage>54</lpage>.</mixed-citation></ref></ref-list></back></article>